WO2021187486A1 - オキサジアゾール誘導体 - Google Patents
オキサジアゾール誘導体 Download PDFInfo
- Publication number
- WO2021187486A1 WO2021187486A1 PCT/JP2021/010628 JP2021010628W WO2021187486A1 WO 2021187486 A1 WO2021187486 A1 WO 2021187486A1 JP 2021010628 W JP2021010628 W JP 2021010628W WO 2021187486 A1 WO2021187486 A1 WO 2021187486A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- oxadiazole
- alkyl
- substituted
- cycloalkyl
- Prior art date
Links
- 150000004866 oxadiazoles Chemical class 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 322
- 150000003839 salts Chemical class 0.000 claims abstract description 75
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 69
- 206010015037 epilepsy Diseases 0.000 claims abstract description 58
- 201000010099 disease Diseases 0.000 claims abstract description 42
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 39
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 37
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 30
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 23
- 239000001257 hydrogen Substances 0.000 claims abstract description 23
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 108
- 239000011737 fluorine Substances 0.000 claims description 85
- 229910052731 fluorine Inorganic materials 0.000 claims description 85
- 125000003545 alkoxy group Chemical group 0.000 claims description 71
- 239000003814 drug Substances 0.000 claims description 71
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 59
- 125000001424 substituent group Chemical group 0.000 claims description 56
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 47
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 45
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 41
- 125000001153 fluoro group Chemical group F* 0.000 claims description 40
- 229940079593 drug Drugs 0.000 claims description 39
- 229910052799 carbon Inorganic materials 0.000 claims description 38
- 150000002367 halogens Chemical class 0.000 claims description 36
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 33
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 33
- 125000000623 heterocyclic group Chemical group 0.000 claims description 33
- 229940124597 therapeutic agent Drugs 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 29
- 208000035475 disorder Diseases 0.000 claims description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
- 210000000653 nervous system Anatomy 0.000 claims description 26
- 239000001961 anticonvulsive agent Substances 0.000 claims description 25
- 125000004432 carbon atom Chemical group C* 0.000 claims description 25
- 125000005842 heteroatom Chemical group 0.000 claims description 22
- 208000019901 Anxiety disease Diseases 0.000 claims description 21
- 208000020401 Depressive disease Diseases 0.000 claims description 21
- 230000036506 anxiety Effects 0.000 claims description 21
- 230000003449 preventive effect Effects 0.000 claims description 21
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 20
- 239000000460 chlorine Substances 0.000 claims description 20
- 229910052801 chlorine Inorganic materials 0.000 claims description 20
- 208000018737 Parkinson disease Diseases 0.000 claims description 17
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 14
- 230000004064 dysfunction Effects 0.000 claims description 14
- 208000020925 Bipolar disease Diseases 0.000 claims description 13
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 13
- 229910052794 bromium Inorganic materials 0.000 claims description 13
- 208000020685 sleep-wake disease Diseases 0.000 claims description 12
- 229960003965 antiepileptics Drugs 0.000 claims description 11
- 208000020016 psychiatric disease Diseases 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 208000012902 Nervous system disease Diseases 0.000 claims description 9
- 201000000980 schizophrenia Diseases 0.000 claims description 9
- 208000019116 sleep disease Diseases 0.000 claims description 9
- 201000010901 lateral sclerosis Diseases 0.000 claims description 8
- 208000005264 motor neuron disease Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 claims description 8
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 7
- 201000002832 Lewy body dementia Diseases 0.000 claims description 7
- 239000000935 antidepressant agent Substances 0.000 claims description 7
- LSUHDGBXXSQFPX-JTQLQIEISA-N CN([C@@H](CC1)C2=NC(C(C=C3)=CC=C3F)=NO2)C1=O Chemical compound CN([C@@H](CC1)C2=NC(C(C=C3)=CC=C3F)=NO2)C1=O LSUHDGBXXSQFPX-JTQLQIEISA-N 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- LSUHDGBXXSQFPX-SNVBAGLBSA-N CN([C@H](CC1)C2=NC(C(C=C3)=CC=C3F)=NO2)C1=O Chemical compound CN([C@H](CC1)C2=NC(C(C=C3)=CC=C3F)=NO2)C1=O LSUHDGBXXSQFPX-SNVBAGLBSA-N 0.000 claims description 5
- 208000027626 Neurocognitive disease Diseases 0.000 claims description 5
- 201000001119 neuropathy Diseases 0.000 claims description 5
- 230000007823 neuropathy Effects 0.000 claims description 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 5
- 238000001228 spectrum Methods 0.000 claims description 5
- JLIAMHGTQQMFAD-UHFFFAOYSA-N CC(C)(C(N)=O)C1=NC(C(C=C2)=CC=C2Br)=NO1 Chemical compound CC(C)(C(N)=O)C1=NC(C(C=C2)=CC=C2Br)=NO1 JLIAMHGTQQMFAD-UHFFFAOYSA-N 0.000 claims description 4
- GPLWMBSCMHAUHS-UHFFFAOYSA-N CC(C)(C(N)=O)C1=NC(C(C=C2)=CC=C2Cl)=NO1 Chemical compound CC(C)(C(N)=O)C1=NC(C(C=C2)=CC=C2Cl)=NO1 GPLWMBSCMHAUHS-UHFFFAOYSA-N 0.000 claims description 4
- OYJIMJHTMMGHLC-UHFFFAOYSA-N CC(C)(C(N)=O)C1=NOC(C(C=C2)=CC=C2Cl)=N1 Chemical compound CC(C)(C(N)=O)C1=NOC(C(C=C2)=CC=C2Cl)=N1 OYJIMJHTMMGHLC-UHFFFAOYSA-N 0.000 claims description 4
- SABBWWFAYAYSNM-UHFFFAOYSA-N CC(C)S(NC1=NOC(C(C=C2)=CC=C2Cl)=N1)(=O)=O Chemical compound CC(C)S(NC1=NOC(C(C=C2)=CC=C2Cl)=N1)(=O)=O SABBWWFAYAYSNM-UHFFFAOYSA-N 0.000 claims description 4
- SFPCJVKSICJFAU-UHFFFAOYSA-N CN(C(CC1)C2=NC(C(C=C3)=CC=C3Cl)=NO2)C1=O Chemical compound CN(C(CC1)C2=NC(C(C=C3)=CC=C3Cl)=NO2)C1=O SFPCJVKSICJFAU-UHFFFAOYSA-N 0.000 claims description 4
- LSUHDGBXXSQFPX-UHFFFAOYSA-N FC1=CC=C(C2=NOC(=N2)C2N(C(=O)CC2)C)C=C1 Chemical compound FC1=CC=C(C2=NOC(=N2)C2N(C(=O)CC2)C)C=C1 LSUHDGBXXSQFPX-UHFFFAOYSA-N 0.000 claims description 4
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims description 4
- 230000000561 anti-psychotic effect Effects 0.000 claims description 4
- 229940005513 antidepressants Drugs 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- SQQWBSBBCSFQGC-JLHYYAGUSA-N ubiquinone-2 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CCC=C(C)C)=C(C)C1=O SQQWBSBBCSFQGC-JLHYYAGUSA-N 0.000 claims description 4
- DTWWPCXVUFRLGF-UHFFFAOYSA-N CC(C)(C(N)=O)C1=NC(C(C=C2)=CC=C2F)=NO1 Chemical compound CC(C)(C(N)=O)C1=NC(C(C=C2)=CC=C2F)=NO1 DTWWPCXVUFRLGF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000164 antipsychotic agent Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- RVMXAPXUVJFJPG-UHFFFAOYSA-N CC(C)(C(N)=O)C1=NN=C(C(C=C2)=CC=C2Br)O1 Chemical compound CC(C)(C(N)=O)C1=NN=C(C(C=C2)=CC=C2Br)O1 RVMXAPXUVJFJPG-UHFFFAOYSA-N 0.000 claims description 2
- FVVKRUCCHAENKF-UHFFFAOYSA-N CC(C)(C(N)=O)C1=NN=C(O1)C1=CC=C(Cl)C=C1 Chemical compound CC(C)(C(N)=O)C1=NN=C(O1)C1=CC=C(Cl)C=C1 FVVKRUCCHAENKF-UHFFFAOYSA-N 0.000 claims description 2
- DQECQNWSOWPOIX-UHFFFAOYSA-N CC(C)(C(N)=O)C1=NOC(C(C=C2)=CC=C2Br)=N1 Chemical compound CC(C)(C(N)=O)C1=NOC(C(C=C2)=CC=C2Br)=N1 DQECQNWSOWPOIX-UHFFFAOYSA-N 0.000 claims description 2
- BFZNFLYLLPZHQV-UHFFFAOYSA-N CC(C)(C(N)=O)C1=NOC(C(C=C2)=CC=C2F)=N1 Chemical compound CC(C)(C(N)=O)C1=NOC(C(C=C2)=CC=C2F)=N1 BFZNFLYLLPZHQV-UHFFFAOYSA-N 0.000 claims description 2
- BCMHKTWQLIKFIG-UHFFFAOYSA-N CC(C)S(NC1=NC(C(C=C2)=CC=C2Br)=NO1)(=O)=O Chemical compound CC(C)S(NC1=NC(C(C=C2)=CC=C2Br)=NO1)(=O)=O BCMHKTWQLIKFIG-UHFFFAOYSA-N 0.000 claims description 2
- UNIIJXHEOFRXPR-UHFFFAOYSA-N CC(C)S(NC1=NC(C(C=C2)=CC=C2Cl)=NO1)(=O)=O Chemical compound CC(C)S(NC1=NC(C(C=C2)=CC=C2Cl)=NO1)(=O)=O UNIIJXHEOFRXPR-UHFFFAOYSA-N 0.000 claims description 2
- ZYHGABJYUAFJAO-UHFFFAOYSA-N CC(C)S(NC1=NC(C(C=C2)=CC=C2F)=NO1)(=O)=O Chemical compound CC(C)S(NC1=NC(C(C=C2)=CC=C2F)=NO1)(=O)=O ZYHGABJYUAFJAO-UHFFFAOYSA-N 0.000 claims description 2
- QKTQZYHIGIMCPE-UHFFFAOYSA-N CC(C)S(NC1=NN=C(C(C=C2)=CC=C2Br)O1)(=O)=O Chemical compound CC(C)S(NC1=NN=C(C(C=C2)=CC=C2Br)O1)(=O)=O QKTQZYHIGIMCPE-UHFFFAOYSA-N 0.000 claims description 2
- RPFJFCGRYQLESV-UHFFFAOYSA-N CC(C)S(NC1=NN=C(C(C=C2)=CC=C2Cl)O1)(=O)=O Chemical compound CC(C)S(NC1=NN=C(C(C=C2)=CC=C2Cl)O1)(=O)=O RPFJFCGRYQLESV-UHFFFAOYSA-N 0.000 claims description 2
- JBUOWNOZHVVDNE-UHFFFAOYSA-N CC(C)S(NC1=NN=C(C(C=C2)=CC=C2F)O1)(=O)=O Chemical compound CC(C)S(NC1=NN=C(C(C=C2)=CC=C2F)O1)(=O)=O JBUOWNOZHVVDNE-UHFFFAOYSA-N 0.000 claims description 2
- MTKLPXWWGTUKRB-UHFFFAOYSA-N CC(C)S(NC1=NOC(C(C=C2)=CC=C2Br)=N1)(=O)=O Chemical compound CC(C)S(NC1=NOC(C(C=C2)=CC=C2Br)=N1)(=O)=O MTKLPXWWGTUKRB-UHFFFAOYSA-N 0.000 claims description 2
- CXINYPBHGHUNNO-UHFFFAOYSA-N CC(CC1)(C2=NC(C(C=C3)=CC=C3F)=NO2)N(C)C1=O Chemical compound CC(CC1)(C2=NC(C(C=C3)=CC=C3F)=NO2)N(C)C1=O CXINYPBHGHUNNO-UHFFFAOYSA-N 0.000 claims description 2
- PEXPCHVFQVQOFW-UHFFFAOYSA-N CCC(CC)(C(N)=O)C1=NC(C(C=C2)=CC=C2Cl)=NO1 Chemical compound CCC(CC)(C(N)=O)C1=NC(C(C=C2)=CC=C2Cl)=NO1 PEXPCHVFQVQOFW-UHFFFAOYSA-N 0.000 claims description 2
- LBIQJKBIOPXVAE-UHFFFAOYSA-N CN(C(CC1)C2=NC(C(C=C3)=CC(F)=C3F)=NO2)C1=O Chemical compound CN(C(CC1)C2=NC(C(C=C3)=CC(F)=C3F)=NO2)C1=O LBIQJKBIOPXVAE-UHFFFAOYSA-N 0.000 claims description 2
- FMBUDAQMTCYWKH-UHFFFAOYSA-N CN(C(CC1)C2=NC(C(C=C3)=CC=C3Br)=NO2)C1=O Chemical compound CN(C(CC1)C2=NC(C(C=C3)=CC=C3Br)=NO2)C1=O FMBUDAQMTCYWKH-UHFFFAOYSA-N 0.000 claims description 2
- XGTXJUOAOHWDQA-UHFFFAOYSA-N CN(C(CC1)C2=NC(C(C=CC(F)=C3)=C3F)=NO2)C1=O Chemical compound CN(C(CC1)C2=NC(C(C=CC(F)=C3)=C3F)=NO2)C1=O XGTXJUOAOHWDQA-UHFFFAOYSA-N 0.000 claims description 2
- RELGKEDWPAYFSM-UHFFFAOYSA-N NC(C(C1)(CC1(F)F)C1=NC(C(C=C2)=CC=C2Cl)=NO1)=O Chemical compound NC(C(C1)(CC1(F)F)C1=NC(C(C=C2)=CC=C2Cl)=NO1)=O RELGKEDWPAYFSM-UHFFFAOYSA-N 0.000 claims description 2
- RABGGNMIUOUFMS-UHFFFAOYSA-N NC(C(C1)(CC1F)C1=NC(C(C=C2)=CC=C2Cl)=NO1)=O Chemical compound NC(C(C1)(CC1F)C1=NC(C(C=C2)=CC=C2Cl)=NO1)=O RABGGNMIUOUFMS-UHFFFAOYSA-N 0.000 claims description 2
- HVYYKGZFCYWQHL-UHFFFAOYSA-N O=C(C1CC1)NC1=NC(C(C=C2)=CC=C2Cl)=NO1 Chemical compound O=C(C1CC1)NC1=NC(C(C=C2)=CC=C2Cl)=NO1 HVYYKGZFCYWQHL-UHFFFAOYSA-N 0.000 claims description 2
- FNXGFENCWOODGV-UHFFFAOYSA-N O=C(C1CC1)NC1=NC(C(C=C2)=CC=C2F)=NO1 Chemical compound O=C(C1CC1)NC1=NC(C(C=C2)=CC=C2F)=NO1 FNXGFENCWOODGV-UHFFFAOYSA-N 0.000 claims description 2
- ACCIMZJJSHDLOP-UHFFFAOYSA-N O=C(C1CCC1)NC1=NC(C(C=C2)=CC=C2Cl)=NO1 Chemical compound O=C(C1CCC1)NC1=NC(C(C=C2)=CC=C2Cl)=NO1 ACCIMZJJSHDLOP-UHFFFAOYSA-N 0.000 claims description 2
- HZSPEWZTKJOZKH-UHFFFAOYSA-N O=C(C1CCCC1)NC1=NC(C(C=C2)=CC=C2Cl)=NO1 Chemical compound O=C(C1CCCC1)NC1=NC(C(C=C2)=CC=C2Cl)=NO1 HZSPEWZTKJOZKH-UHFFFAOYSA-N 0.000 claims description 2
- FJIGNNKTANPAGG-UHFFFAOYSA-N O=C(C1CCOCC1)NC1=NC(C(C=C2)=CC=C2F)=NO1 Chemical compound O=C(C1CCOCC1)NC1=NC(C(C=C2)=CC=C2F)=NO1 FJIGNNKTANPAGG-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- 229940005529 antipsychotics Drugs 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 abstract description 12
- 230000000069 prophylactic effect Effects 0.000 abstract description 12
- 230000001225 therapeutic effect Effects 0.000 abstract description 12
- 125000005843 halogen group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 100
- 206010010904 Convulsion Diseases 0.000 description 68
- -1 1-methylpentyl Chemical group 0.000 description 65
- 239000002904 solvent Substances 0.000 description 56
- 238000004519 manufacturing process Methods 0.000 description 54
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 51
- 238000006243 chemical reaction Methods 0.000 description 48
- 238000012360 testing method Methods 0.000 description 47
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 46
- 239000002994 raw material Substances 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 37
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- 239000000203 mixture Substances 0.000 description 33
- 239000000243 solution Substances 0.000 description 31
- 150000001721 carbon Chemical group 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 21
- 102000004300 GABA-A Receptors Human genes 0.000 description 20
- 108090000839 GABA-A Receptors Proteins 0.000 description 20
- 230000003213 activating effect Effects 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000012046 mixed solvent Substances 0.000 description 17
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 230000001773 anti-convulsant effect Effects 0.000 description 15
- 208000011580 syndromic disease Diseases 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- 201000007547 Dravet syndrome Diseases 0.000 description 12
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 12
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000018044 dehydration Effects 0.000 description 12
- 238000006297 dehydration reaction Methods 0.000 description 12
- 230000035484 reaction time Effects 0.000 description 12
- 238000007363 ring formation reaction Methods 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 229940049706 benzodiazepine Drugs 0.000 description 11
- 238000009833 condensation Methods 0.000 description 11
- 230000005494 condensation Effects 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 208000002091 Febrile Seizures Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 9
- 230000002920 convulsive effect Effects 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 208000008233 autosomal dominant nocturnal frontal lobe epilepsy Diseases 0.000 description 8
- 230000036760 body temperature Effects 0.000 description 8
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 8
- 229940011051 isopropyl acetate Drugs 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 7
- 206010054089 Depressive symptom Diseases 0.000 description 7
- 241000004297 Draba Species 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010061334 Partial seizures Diseases 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 238000010254 subcutaneous injection Methods 0.000 description 7
- 239000007929 subcutaneous injection Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 6
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 6
- 206010043994 Tonic convulsion Diseases 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 150000008065 acid anhydrides Chemical class 0.000 description 6
- 229910052783 alkali metal Inorganic materials 0.000 description 6
- 230000001430 anti-depressive effect Effects 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- 230000036461 convulsion Effects 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 206010014599 encephalitis Diseases 0.000 description 6
- 230000000422 nocturnal effect Effects 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- 0 *C(**1)*C1c(cc1)ccc1I Chemical compound *C(**1)*C1c(cc1)ccc1I 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 206010003805 Autism Diseases 0.000 description 5
- 208000020706 Autistic disease Diseases 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 208000012239 Developmental disease Diseases 0.000 description 5
- 206010063629 Hippocampal sclerosis Diseases 0.000 description 5
- 206010021750 Infantile Spasms Diseases 0.000 description 5
- 208000035899 Infantile spasms syndrome Diseases 0.000 description 5
- 201000006791 West syndrome Diseases 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 150000001557 benzodiazepines Chemical class 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 5
- 229960004381 flumazenil Drugs 0.000 description 5
- 201000007186 focal epilepsy Diseases 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 230000002123 temporal effect Effects 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960003529 diazepam Drugs 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 206010028289 Muscle atrophy Diseases 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010037180 Psychiatric symptoms Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 208000027568 Trauma and Stressor Related disease Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 description 3
- 206010016284 febrile convulsion Diseases 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000020763 muscle atrophy Effects 0.000 description 3
- 201000000585 muscular atrophy Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 206010001541 Akinesia Diseases 0.000 description 2
- 208000009575 Angelman syndrome Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000030336 Bipolar and Related disease Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 2
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001035 methylating effect Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000003892 tartrate salts Chemical class 0.000 description 2
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- XUJHKPSBHDQIOD-UHFFFAOYSA-N (2-bromo-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl)methanesulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)C(Br)C1C2(C)C XUJHKPSBHDQIOD-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- YMYLGVIBUGDMLT-QMMMGPOBSA-N (2s)-2-(phenylmethoxyamino)propanoic acid Chemical compound OC(=O)[C@H](C)NOCC1=CC=CC=C1 YMYLGVIBUGDMLT-QMMMGPOBSA-N 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical group C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- IZWMZVDEYOKQCG-UHFFFAOYSA-N 1-(2,4-dimethoxyphenyl)-n-[(2,4-dimethoxyphenyl)methyl]methanamine Chemical compound COC1=CC(OC)=CC=C1CNCC1=CC=C(OC)C=C1OC IZWMZVDEYOKQCG-UHFFFAOYSA-N 0.000 description 1
- XYHZRSFKDSWLHW-UHFFFAOYSA-N 1-ethoxycarbonylcyclobutane-1-carboxylic acid Chemical compound CCOC(=O)C1(C(O)=O)CCC1 XYHZRSFKDSWLHW-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- QBGZOSPLOUPRQG-UHFFFAOYSA-N 3-(4-bromophenyl)-5-(chloromethyl)-1,2,4-oxadiazole Chemical compound O1C(CCl)=NC(C=2C=CC(Br)=CC=2)=N1 QBGZOSPLOUPRQG-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- QBGONPQFBDUVPG-UHFFFAOYSA-N 4-chloro-n'-hydroxybenzenecarboximidamide Chemical compound ON=C(N)C1=CC=C(Cl)C=C1 QBGONPQFBDUVPG-UHFFFAOYSA-N 0.000 description 1
- PKBGHORNUFQAAW-UHFFFAOYSA-N 4-chlorobenzohydrazide Chemical compound NNC(=O)C1=CC=C(Cl)C=C1 PKBGHORNUFQAAW-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- MCRNHLQVPJEMSQ-UHFFFAOYSA-N C(C=CC(=O)O)(=O)O.C(CCCCCCCCCCCCCCCCC)[Na] Chemical compound C(C=CC(=O)O)(=O)O.C(CCCCCCCCCCCCCCCCC)[Na] MCRNHLQVPJEMSQ-UHFFFAOYSA-N 0.000 description 1
- MSYKJVODDRECDR-UHFFFAOYSA-N C1(Cl)=CC=C(C2=NOC(=N2)C(C)(C(=O)O)C)C=C1 Chemical compound C1(Cl)=CC=C(C2=NOC(=N2)C(C)(C(=O)O)C)C=C1 MSYKJVODDRECDR-UHFFFAOYSA-N 0.000 description 1
- YMAFSMIPOPJQAY-UHFFFAOYSA-N C1(F)=CC=C(C2=NOC(=N2)C2NC(=O)CC2)C=C1 Chemical compound C1(F)=CC=C(C2=NOC(=N2)C2NC(=O)CC2)C=C1 YMAFSMIPOPJQAY-UHFFFAOYSA-N 0.000 description 1
- CSNMMNNSBJWRQB-UHFFFAOYSA-N CC(C(O)=O)N(C)C(C)=O Chemical compound CC(C(O)=O)N(C)C(C)=O CSNMMNNSBJWRQB-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000024658 Epilepsy syndrome Diseases 0.000 description 1
- 208000002877 Epileptic Syndromes Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000003078 Generalized Epilepsy Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- IZOWTMSTHJGGCO-UHFFFAOYSA-N N/C(/c(cc1)ccc1I)=N\O Chemical compound N/C(/c(cc1)ccc1I)=N\O IZOWTMSTHJGGCO-UHFFFAOYSA-N 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000028311 absence seizure Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 239000000749 benzodiazepine receptor blocking agent Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000007357 depressive behavior Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- WJDYAEIVFPVODA-UHFFFAOYSA-N ethyl (3z)-3-amino-3-hydroxyiminopropanoate Chemical compound CCOC(=O)CC(N)=NO WJDYAEIVFPVODA-UHFFFAOYSA-N 0.000 description 1
- NAERMZUIUQCKNK-UHFFFAOYSA-N ethyl 1-carbonochloridoylcyclobutane-1-carboxylate Chemical compound CCOC(=O)C1(C(Cl)=O)CCC1 NAERMZUIUQCKNK-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 150000002238 fumaric acids Chemical class 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- CBCIHIVRDWLAME-UHFFFAOYSA-N hexanitrodiphenylamine Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O CBCIHIVRDWLAME-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 239000012022 methylating agents Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- WBGPDYJIPNTOIB-UHFFFAOYSA-N n,n-dibenzylethanamine Chemical compound C=1C=CC=CC=1CN(CC)CC1=CC=CC=C1 WBGPDYJIPNTOIB-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001225 nuclear magnetic resonance method Methods 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 229950004193 perospirone Drugs 0.000 description 1
- GTAIPSDXDDTGBZ-OYRHEFFESA-N perospirone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCN3C(=O)[C@@H]4CCCC[C@@H]4C3=O)=NSCC2=C1 GTAIPSDXDDTGBZ-OYRHEFFESA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- NSETWVJZUWGCKE-UHFFFAOYSA-N propylphosphonic acid Chemical compound CCCP(O)(O)=O NSETWVJZUWGCKE-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
- 229960005318 vigabatrin Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to a oxadiazole derivative useful as a drug, a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing them as an active ingredient, or a therapeutic agent for a disease such as epilepsy and / or depressive syndrome, and / or. Regarding preventive agents.
- Epilepsy is a chronic disease in which unusual physical symptoms, movements, consciousness, and sensory changes suddenly and repeatedly occur due to hyperexcitability of nerve cells in the cerebrum. Seizure types are classified by the International Federation of Anti-Epilepsy (ILAE) into generalized seizures, focal seizures, and unclassified seizures, and generalized seizures are further classified into tonic seizures, interstitial seizures, deficiency seizures, myocrony seizures, and weakness seizures. (Non-Patent Document 1). Pathogenesis that is the background of the disease is roughly classified into genetic, structural / metabolic, and unknown cause. In addition, epilepsy is classified into various types and syndromes based on characteristics such as electroencephalogram / clinical symptoms, age of onset, and pathogenesis.
- Non-Patent Document 2 Since the 1990s, international joint research on molecular pathology analysis of epilepsy has progressed, and many causative genes have been identified to date. These genes include ion channels such as Na, K, Ca, Cl, GABA-A, and ACh, and it is inferred that epilepsy develops due to abnormal ion homeostasis as one cause.
- Epilepsy is a serious disease that also affects the prognosis of life and is known to affect about 1% of the world's population. Treatment of these epilepsy attacks is centered on drug treatment, and despite the fact that various antiepileptic drugs have been prescribed for a long time, one in three cases of epilepsy shows resistance to multidrug treatment with existing drugs. Refractory epilepsy. In addition, existing drugs have dose-dependent side effects on the nervous system such as excessive drowsiness, light-headedness, cognitive impairment, and psychological symptoms, and rare but severe idiosyncratic side effects such as Stevens-Johnson syndrome and teratogenicity.
- Non-Patent Document 3 Non-Patent Document 3
- existing drugs have no therapeutic effect on these comorbid psychiatric symptoms.
- Epilepsy presents with seizures due to hyperexcitability of cranial nerve cells, but the excitatory nerves work strongly or the inhibitory nerves weaken, that is, the balance between excitatory (E) and inhibitory (I) (E / I balance). It is believed that the cause is an abnormality in.
- E excitatory
- I inhibitory
- GABA nervous system activators that activate inhibitory nerves have been shown to have therapeutic effects on anxiety, obsessive-compulsive disorder, and REM sleep disorder associated with Parkinson's disease and Lewy body dementias.
- E / I imbalance is also involved in neuropathic pain, developmental disorders, autism, bipolar disorder, schizophrenia, Alzheimer's disease and other dementia, muscular atrophic lateral sclerosis, Parkinson's disease, etc. It is known to do.
- some antiepileptic drugs that improve E / I imbalance have been widely applied to these other diseases.
- the drug efficacy intensity in diseases other than these epilepsy is also limited, and side effects and pharmacokinetic issues remain. Therefore, antiepileptic drugs with new efficacy / side effect profiles may be applicable to many of these psychiatric and nervous system diseases, and their development is of great significance.
- Patent Document 1 describes oxadiazoles having a sweetness-modifying effect, but their chemical structures are different from those of the compound represented by the formula (1) described later.
- An object of the present invention is to provide a compound useful as an antiepileptic drug.
- an oxadiazole derivative represented by the following formula (1) (hereinafter, may be referred to as “compound of the present invention”) is provided.
- the present invention is as follows.
- [Item 1] A compound represented by the formula (1) or a pharmaceutically acceptable salt thereof.
- Q 1 represents a halogen
- Q 2 is hydrogen, halogen, cyano, C 1-3 alkyl (said alkyl is halogen, hydroxyl, C 3-6 1 ⁇ 3 substituents independently selected from the group consisting of cycloalkyl and C 1-3 alkoxy 1-3 alkoxy (which may be substituted with a group) or 1-3 alkoxys independently selected from the group consisting of halogens, hydroxyl groups, C 3-6 cycloalkyls and C 1-3 alkoxys.
- X, Y and Z represent the same or different nitrogen atom or oxygen atom, except that in the ring containing X, Y and Z, two of X, Y and Z are nitrogen atoms and the remaining one.
- R 2 and R 3 are the same or different and are independently selected from the group consisting of C 1-6 alkyl (where the alkyl consists of halogen, hydroxyl group, C 3-6 cycloalkyl and C 1-3 alkoxy) 1-3 It may be substituted with multiple substituents) or C 3-6 cycloalkyl (the cycloalkyl is independently selected from the group consisting of halogens, hydroxyl groups, C 1-3 alkyl and C 1-3 alkoxy. Represents (may be substituted with 1 to 3 substituents) or C 3-6 cycloalkyl (where the cycloalkyl is halogen, hydroxyl group, C 1-) together with the carbon atom to which they are attached.
- R 4 and R 5 are the same or different and are independent of the group consisting of hydrogen, halogen, hydroxyl group, C 1-6 alkyl (the alkyl is halogen, hydroxyl group, C 3-6 cycloalkyl and C 1-3 alkoxy).
- C 3-6 cycloalkyl the cycloalkyl consists of halogens, hydroxyl groups, C 1-3 alkyl and C 1-3 alkoxy. (May be substituted with 1 to 3 independently selected substituents), or if R 4 and R 5 are on the same or adjacent carbon atoms, they C 3-6 cycloalkyl (the cycloalkyl is selected independently from the group consisting of halogen, hydroxyl group, C 1-3 alkyl and C 1-3 alkoxy) together with the carbon atom to which the is bonded.
- n represents an integer of 0 to 2.
- R 2 and R 3 are the same or different and are independently selected from the group consisting of C 1-3 alkyl (the alkyl consists of fluorine, hydroxyl group and C 1-3 alkoxy). It represents C 3-6 cycloalkyl (which may be substituted with a group) or together with the carbon atom to which they are attached (the cycloalkyl is fluorine, hydroxyl group, C 1-3 alkyl and C 1-. It may be substituted with 1 to 3 substituents independently selected from the group consisting of 3 alkoxys), or 1 or independently selected from the group consisting of nitrogen and oxygen atoms.
- R 2 and R 3 represent the same or different C 1-3 alkyl (the alkyl may be substituted with fluorine), or together with the carbon atom to which they are attached.
- C 3-6 cycloalkyl (the cycloalkyl may be substituted with fluorine), or one or two heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms. It is a group constituting a C 4-6 saturated heterocycle containing (the saturated heterocycle may be substituted with fluorine).
- Item 2 The compound according to Item 2 or a pharmaceutically acceptable salt thereof.
- R 4 and R 5 are the same or different and are independently selected from the group consisting of hydrogen, fluorine, hydroxyl group, C 1-3 alkyl (the alkyl is fluorine, hydroxyl group, and C 1-3 alkoxy). It may be substituted with 1 to 3 substituents), or C 3-6 cycloalkyl (the cycloalkyl is independent of the group consisting of fluorine, hydroxyl group, C 1-3 alkyl and C 1-3 alkoxy.
- 1-3 represent a may) be substituted with a substituent selected Te, or when present on carbon atoms R 4 and R 5 are the same on a carbon atom or adjacent, they are attached C 3-6 cycloalkyl (where cycloalkyl is selected independently from the group consisting of fluorine, hydroxyl group, C 1-3 alkyl and C 1-3 alkoxy) with 1 to 3 substitutions
- the ring forms a group constituting (which may be substituted with 1 to 3 substituents independently selected from the group consisting of fluorine, hydroxyl group, C 1-3 alkyl and C 1-3 alkoxy).
- Good, Item 2. The compound according to any one of Items 1 to 3 or a pharmaceutically acceptable salt thereof.
- R 4 and R 5 are the same or different, hydrogen, fluorine, hydroxyl group, C 1-3 alkyl (the alkyl may be substituted with fluorine), or C 3-6 cycloalkyl (the alkyl). Cycloalkyl may be substituted with fluorine), or if R 4 and R 5 are on the same or adjacent carbon atoms, they will be combined with the carbon atom to which they are attached. Form a group constituting C 3-6 cycloalkyl (the cycloalkyl may be substituted with 1 to 3 substituents independently selected from the group consisting of fluorine and C 1-3 alkyl). May, Item 4. The compound according to Item 4 or a pharmaceutically acceptable salt thereof.
- Q 1 is fluorine, chlorine or bromine
- Q 2 is hydrogen, fluorine, chlorine, bromine, cyano, C 1-3 alkyl (the alkyl may be substituted with fluorine) or C 1-3 alkoxy (said alkoxy may be substituted with fluorine) Is, Item 2.
- R 1 is the following (2) or (3).
- Item 2 The compound according to any one of Items 1 to 3 or 6 to 8, or a pharmaceutically acceptable salt thereof.
- R 1 is the following (4).
- Item 1 The compound according to any one of Items 1 or 4 to 8, or a pharmaceutically acceptable salt thereof.
- a therapeutic agent and / or a preventive agent for a nervous system disease or a psychiatric disease which comprises the compound according to any one of Items 1 to 12 or a pharmaceutically acceptable salt thereof as an active ingredient.
- a therapeutic agent and / or a therapeutic agent for a disease associated with GABA nervous system dysfunction which comprises the compound according to any one of Items 1 to 12 or a pharmaceutically acceptable salt thereof as an active ingredient.
- Preventive agent Preventive agent.
- Epileptic seizures (tonic seizures, interstitial seizures, deficiency seizures, myochrony seizures, generalized seizures including weakness seizures, focal seizures, unclassified seizures), epileptic seizures, waist Syndrome, Drave syndrome, Lennox-Gasteau syndrome, autosomal dominant nocturnal frontal epilepsy (ADNFLE), medial temporal lobar epilepsy with hippocampal sclerosis as a distinct group of specific symptoms, Rasmussen syndrome, depressive symptoms with or without epilepsy , Anxiety, obsessive disorder, REM sleep disorder associated with Parkinson's disease / Levy body dementia, neuropathy pain, developmental disorder, autism, bipolar disorder, schizophrenia, Alzheimer's disease and other dementia, muscle Item 4.
- Nervous system or psychiatric disorders include epilepsy, neuropathy pain, neurodevelopmental disorders, bipolar disorders and related disorders, schizophrenia spectrum disorders, Alzheimer's disease and other neurocognitive disorders, muscle atrophy. Lateral sclerosis, Parkinson's disease, depressive syndrome, anxiety group, compulsive disorder, trauma and stress-related disorders, sleep-wake disorder group, and / or REM sleep disorder associated with Parkinson's disease / Lewy body dementias Item 14. The therapeutic agent and / or preventive agent according to Item 14 or 17.
- GABA nerve which comprises administering to a patient in need of treatment a therapeutically effective amount of the compound according to any one of items 1 to 12, or a pharmaceutically acceptable salt thereof.
- Epilepsy epileptic seizures (tonic seizures, interstitial seizures, deficiency seizures, myochrony seizures, generalized seizures including weakness seizures, focal epilepsy, unclassified seizures), epilepsy accumulation, waist syndrome, Dravet syndrome, Item 23.
- the therapeutic agent and / or the therapeutic agent according to Item 23 Lenox-Gasteau syndrome, autosomal dominant nocturnal frontal epilepsy (ADNFLE), medial temporal epilepsy with hippocampal sclerosis as a distinct group of specific symptoms, or Rasmussen syndrome. Prophylactic agent.
- a disease associated with GABA nervous system dysfunction which is characterized by being used in combination with at least one drug selected from drugs classified as antiepileptic drugs, antidepressants, or antipsychotic drugs.
- the compound of the present invention showed strong anticonvulsant activity in a plurality of convulsive model animals (subcutaneous injection pentetrazole model of Test Example 1 and febrile seizure of Drave model mouse of Test Example 3) caused by a decrease in GABA signal. ..
- the subcutaneous injection pentetrazole model of Test Example 1 is an expression system of general absence seizures and myoclonic seizures, and is a model exhibiting a seizure type in which the remission rate of existing antiepileptic drugs is low.
- the Dravet model mouse febrile convulsions of Test Example 3 is an animal model having the same genetic background as Dravet syndrome exhibiting treatment-resistant convulsions, and the effect of existing antiepileptic drugs on the model is very limited.
- the compounds of the present invention include epilepsy (eg, epilepsy (eg, tonic, dravet, dravet, myoclony, general epilepsy, including weakness, focal epilepsy, unclassified epilepsy), epilepsy, waist ( West syndrome, Dravet syndrome, Lennox-Gastaut syndrome, autosomal dominant nocturnal frontal epilepsy (ADNFLE), medial temporal epilepsy with hippocampal sclerosis as a distinct group of specific symptoms, Rasmussen It is useful as a prophylactic and / or therapeutic agent for (Rasmussen) syndrome, etc.).
- epilepsy eg, epilepsy (eg, tonic, dravet, dravet, myoclony, general epilepsy, including weakness, focal epilepsy, unclassified epilepsy
- epilepsy eg, waist ( West syndrome, Dravet syndrome, Lennox-Gastaut syndrome, autosomal dominant nocturnal frontal
- West syndrome, Dravet syndrome, and Lennox-Gastaut syndrome are serious diseases that present with treatment-resistant convulsions and are accompanied by developmental delay, etc., and provide preventive and / or therapeutic agents for intractable epilepsy including these. Is of great significance.
- the GABA-A receptor activating activity of the compound of the present invention is exhibited in a mode of action different from that of benzodiazepine, which is one of the existing GABA nervous system activators, and a rat forced swimming model showing no effect with benzodiazepine. Since it was effective against depressive symptoms (Test Example 5), it is effective against depressive symptoms that occur with or without epilepsy, and has usefulness that existing antiepileptic drugs do not have.
- the compound of the present invention has GABA-A receptor activating activity, it can be used for anxiety, compulsive disorder, Parkinson's disease and Lewy body dementias, which are recognized to have therapeutic effects by existing GABA nervous system activators. It is also useful as a prophylactic and / or therapeutic agent for the associated REM sleep disorder. In addition, pathological conditions for neuropathic pain, developmental disorders, autism, bipolar disorder, schizophrenia, Alzheimer's disease and other dementia, muscle atrophy lateral sclerosis, and Parkinson's disease due to abnormalities in the GABA nervous system. It is thought that it will exert an improvement effect. In addition, it is also useful as a prophylactic and / or therapeutic agent for the other diseases described herein.
- the compound of the present invention has an action of strengthening inhibition (I) in the balance (E / I balance) of excitement (E) and inhibition (I), it is a therapeutic agent and / or a therapeutic agent for nervous system diseases or psychiatric disorders. It can be a prophylactic agent, in particular a therapeutic and / or prophylactic agent for diseases in which excitement (E) in the E / I balance is increased and / or suppressed (I) is decreased.
- each group also applies when the group is a part or a substituent of another group.
- halogen examples include fluorine, chlorine, bromine, and iodine. Fluorine, chlorine, or bromine is preferred. More preferably, it is fluorine or chlorine, and even more preferably, it is fluorine.
- C 1-6 alkyl means a linear or branched saturated hydrocarbon group having 1 to 6 carbon atoms
- C 6 alkyl means an alkyl having 6 carbon atoms. Means. The same applies to other numbers.
- C 1-6 alkyl preferably “C 1-3 alkyl” is mentioned, and more preferably “C 1-2 alkyl” is mentioned.
- C 1-3 alkyl preferably “C 1-2 alkyl” is mentioned, and more preferably methyl is mentioned.
- Specific examples of "C 1-2 alkyl” include, for example, methyl, ethyl and the like.
- C 1-3 alkyl include, for example, propyl, 1-methylethyl and the like in addition to those mentioned as specific examples of “C 1-2 alkyl”.
- C 1-6 alkyl include, for example, butyl, 1,1-dimethylethyl, 1-methylpropyl, and 2-methyl, in addition to those listed as specific examples of "C 1-3 alkyl”.
- the “C 3-6 cycloalkyl” means a cyclic alkyl having 3 to 6 carbon atoms, and a partially crosslinked structure is also included.
- the “C 3-6 cycloalkyl” is preferably "C 3-5 cycloalkyl". Specific examples of “C 3-5 cycloalkyl” include cyclopropyl, cyclobutyl, cyclopentyl and the like. Specific examples of “C 3-6 cycloalkyl” include, for example, cyclohexyl and the like in addition to those mentioned as specific examples of "C 3-5 cycloalkyl".
- the “C 1-3 alkoxy” means an oxy group substituted with the “C 1-3 alkyl”.
- the "C 1-3 alkoxy group” preferably “C 1-2 alkoxy” is mentioned, and more preferably “methoxy” is mentioned.
- Specific examples of “C 1-2 Alkoxy” include methoxy, ethoxy and the like.
- Specific examples of “C 1-3 alkoxy” include, for example, propoxy, 1-methylethoxy, and the like, in addition to those mentioned as specific examples of "C 1-2 alkoxy”.
- C 4-6 Saturated Heterocycle means a 4- to 6-membered saturated ring containing one or more identical or different heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. Partially crosslinked structures are also included. Preferably, it is a C 4-6 saturated heterocycle containing one or two heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms.
- the "C 4-6 saturated heterocycle” is preferably a "C 4-5 saturated heterocycle”.
- Specific examples of the "C 4-5 saturated heterocycle” include oxetane, azetidine, tetrahydrofuran, pyrrolidine and the like.
- Specific examples of the "C 4-6 saturated heterocycle” include tetrahydropyran, piperidine, morpholine, piperazine, and the like, in addition to those mentioned as specific examples of the "C 4-5 saturated heterocycle”. ..
- R 1 , R 2 , R 3 , R 4 , R 5 , X, Y, Z, Q 1 , Q 2 and n are preferred as follows, but the technical scope of the present invention is listed below. It is not limited to the range of compounds.
- R 1 examples include the following (2) to (4).
- Another aspect of R 1 includes the following (2) or (3).
- the following (4) can be mentioned.
- R 2 and R 3 are the same or different, (1) C 1-3 alkyl (the alkyl may be substituted with 1 to 3 substituents independently selected from the group consisting of fluorine, hydroxyl groups, and C 1-3 alkoxy). Or, (2) C 3-6 cycloalkyl together with the carbon atom to which R 2 and R 3 are bonded (the cycloalkyl is independent of the group consisting of fluorine, hydroxyl group, C 1-3 alkyl and C 1-3 alkoxy. (May be substituted with 1 to 3 substituents selected in the above), or (3) from the nitrogen atom and the oxygen atom together with the carbon atom to which R 2 and R 3 are bonded.
- R 2 and R 3 are the same or different, (1) C 1-3 alkyl (the alkyl may be substituted with fluorine) or is It consists of (2) a group that constitutes C 3-6 cycloalkyl (the cycloalkyl may be substituted with fluorine) together with the carbon atom to which they are bonded, or (3) a nitrogen atom and an oxygen atom. Examples thereof include groups constituting a C 4-6 saturated heterocycle containing one or two heteroatoms independently selected from the group (the saturated heterocycle may be substituted with fluorine).
- Examples of the C 3-6 cycloalkyl composed together with the carbon atom to which R 2 and R 3 are bonded include the following groups.
- C 4-6 saturated heterocycle composed of the carbon atom to which R 2 and R 3 are bonded
- one or two hetero atoms independently selected from the group consisting of nitrogen atom and oxygen atom are selected.
- Examples include 4- to 6-membered saturated rings containing, for example, the following groups.
- R 4 and R 5 are the same or different, (1) Hydrogen, (2) Fluorine, (3) Hydroxyl group, (4) C 1-3 alkyl (the alkyl may be substituted with 1 to 3 substituents independently selected from the group consisting of fluorine, hydroxyl groups, and C 1-3 alkoxy), (5) C 3-6 cycloalkyl (the cycloalkyl is substituted with 1 to 3 substituents independently selected from the group consisting of fluorine, hydroxyl group, C 1-3 alkyl and C 1-3 alkoxy.
- R 4 and R 5 are the same or different, (1) Hydrogen, (2) Fluorine, (3) Hydroxyl group, (4) C 1-3 alkyl (the alkyl may be substituted with fluorine), (5) C 3-6 cycloalkyl (the cycloalkyl may be substituted with fluorine) or When R 4 and R 5 are on the same carbon atom or on adjacent carbon atoms (6) C 3-6 cycloalkyl together with the carbon atom to which they are attached (the cycloalkyl is 1 to 3 substituents independently selected from the group consisting of fluorine and C 1-3 alkyl. In some cases, a group constituting (which may be substituted) may be formed.
- the C 3-6 cycloalkyl composed together with the carbon atom to which they are bonded includes, for example, the following groups. Can be mentioned.
- the C 4-6 saturated heterocycle formed by combining the carbon atoms to which they are bonded includes, for example, the following groups and the like. Can be mentioned.
- a preferred embodiment of X, Y, Z is the same or different, representing a nitrogen atom or an oxygen atom, except that the ring containing X, Y and Z has two of X, Y and Z being nitrogen atoms.
- the following oxadiazole, the remaining one of which is an oxygen atom, can be mentioned.
- FIG. (5a) ⁇ (5c) the left bond is bonded to the benzene ring, right bond binds to R 1.
- X, Y, Z include the following oxadiazole.
- n examples include integers 0, 1, or 2, and preferred embodiments include 0 or 1.
- Q 1 fluorine, chlorine, bromine, or iodine, more preferably, fluorine, chlorine, or bromine and the like.
- a more preferred aspect of the Q 2 (1) Hydrogen, (2) Fluorine, Examples thereof include (3) chlorine and (4) cyano.
- preferred compounds include the following compounds or pharmaceutically acceptable salts thereof.
- R 1 is one of the following R 2 and R 3 are the same or different, (1) C 1-3 alkyl (the alkyl is substituted with 1 to 3 substituents independently selected from the group consisting of fluorine, hydroxyl group, C 3-6 cycloalkyl and C 1-3 alkoxy. May be good), (2) C 3-6 cycloalkyl (the cycloalkyl is substituted with 1 to 3 substituents independently selected from the group consisting of fluorine, hydroxyl group, C 1-3 alkyl and C 1-3 alkoxy.
- the heteroaryl containing X, Y, and Z is one of the following (5a) to (5c).
- Q 1 is selected from the group consisting of fluorine, chlorine, or bromine
- Q 2 is hydrogen, fluorine, chlorine, cyano, C 1-3 alkyl (said alkyl fluorine, C 3-6 1 ⁇ 3 one independently selected from the group consisting of cycloalkyl and C 1-3 alkoxy 1-3 alkoxys (which may be substituted with substituents) or 1-3 alkoxys independently selected from the group consisting of fluorine, C 3-6 cycloalkyl and C1-3 alkoxys. It may be substituted with a substituent)
- R 1 is the following (4), R 4 and R 5 are the same or different, (1) Hydrogen, (2) Halogen, (3) Hydroxyl group, (4) C 1-3 alkyl (the alkyl is substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl group, C 3-6 cycloalkyl and C 1-3 alkoxy. May be good), (5) C 3-6 cycloalkyl (the cycloalkyl is substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl group, C 1-3 alkyl and C 1-3 alkoxy.
- R 4 and R 5 are present on the carbon atom to which they are bonded or on adjacent carbon atoms, (6) C 3-6 cycloalkyl together with the carbon atom to which they are attached (the cycloalkyl is independently selected from the group consisting of halogens, hydroxyl groups, C 1-3 alkyl and C 1-3 alkoxy. Selected independently from the group consisting of groups constituting (which may be substituted with 1 to 3 substituents), or (7) nitrogen and oxygen atoms together with the carbon atoms to which they are attached.
- C 4-6 saturated heterocycle containing 1 or 2 heteroatoms (1 to 3 said cycloalkyl independently selected from the group consisting of halogen, hydroxyl group, C 1-3 alkyl and C 1-3 alkoxy) It may form a group constituting (which may be substituted with a substituent of).
- the heteroaryl containing X, Y, and Z is one of the following (5a) to (5c).
- Q 1 is selected from the group consisting of fluorine, chlorine, or bromine
- Q 2 is hydrogen, fluorine, chlorine, cyano, C 1-3 alkyl (said alkyl fluorine, C 3-6 1 ⁇ 3 one independently selected from the group consisting of cycloalkyl and C 1-3 alkoxy 1-3 substituents independently selected from the group consisting of fluorine, C 3-6 cycloalkyl and C 1-3 alkoxy (which may be substituted with substituents), C 1-3 alkoxy. It may be substituted with a group)
- a preferred embodiment of n is a compound or a pharmaceutically acceptable salt thereof, which is an integer of 0, 1, or 2.
- R 1 is one of the following R 2 and R 3 are the same or different, (1) C 1-3 alkyl (the alkyl may be substituted with fluorine) or is It consists of (2) a group that constitutes C 3-6 cycloalkyl (the cycloalkyl may be substituted with fluorine) together with the carbon atom to which they are bonded, or (3) a nitrogen atom and an oxygen atom.
- the heteroaryl containing X, Y, Z is (5a) or (5b) below.
- Q 1 is selected from the group consisting of fluorine, chlorine or bromine,
- Q 2 is hydrogen, fluorine, chlorine, a compound or a pharmaceutically acceptable salt thereof is cyano.
- R 1 is the following (4), R 4 and R 5 are the same or different, (1) Hydrogen, (2) Fluorine, (3) Hydroxyl group, (4) C 1-3 alkyl (the alkyl may be substituted with fluorine), (5) C 3-6 cycloalkyl (the cycloalkyl may be substituted with fluorine) or When R 4 and R 5 are on the same carbon atom or on adjacent carbon atoms (6) C 3-6 cycloalkyl together with the carbon atom to which they are attached (the cycloalkyl is 1 to 3 substituents independently selected from the group consisting of fluorine and C 1-3 alkyl.
- the heteroaryl containing X, Y, Z is (5a) or (5b) below.
- Q 1 is selected from the group consisting of fluorine, chlorine or bromine,
- Q 2 is hydrogen, fluorine, chlorine, a compound or a pharmaceutically acceptable salt thereof is cyano.
- Examples of “pharmaceutically acceptable salts” include acid addition salts and base addition salts.
- an inorganic acid salt such as hydrochloride, hydrobromide, sulfate, hydroiodide, nitrate, phosphate, or citrate, oxalate, phthalate, Fumarate, maleate, succinate, malate, acetate, formate, propionate, benzoate, trifluoroacetate, methanesulfonate, benzenesulfonate, para-toluenesulfonic acid
- organic acid salts such as salts and camphor sulfonates.
- the base addition salts include inorganic base salts such as sodium salt, potassium salt, calcium salt, magnesium salt, barium salt and aluminum salt, or trimethylamine, triethylamine, pyridine, picolin, 2,6-rutidine, ethanolamine and diethanolamine. , Triethanolamine, tromethamine [tris (hydroxymethyl) methylamine], tert-butylamine, cyclohexylamine, dicyclohexylamine, N, N-dibenzylethylamine, organic base salts and the like.
- examples of the "pharmaceutically acceptable salt” include amino acid salts with basic amino acids such as arginine, lysine, ornithine, aspartic acid, or glutamic acid or acidic amino acids.
- Suitable salts of raw material compounds and intermediates and acceptable salts as raw materials for pharmaceuticals are conventional non-toxic salts, such as organic acid salts (eg, acetates, trifluoroacetates, maleates, fumaric acids). Salts, citrates, tartrates, methanesulfonates, benzenesulfonates, formates or para-toluenesulfonates, etc.) and inorganic acid salts (eg hydrochlorides, hydrobromide, hydroiodide) , Sulfates, nitrates or phosphates, etc.), salts with amino acids (eg, arginine, aspartic acid or glutamate, etc.), alkali metal salts (eg, sodium or potassium salts, etc.) and alkaline earth metals Metal salts such as salts (eg calcium salt or magnesium salt), ammonium salts, or organic base salts (eg trimethylamine salt, triethylamine salt, pyridine
- the compound of the present invention when it is desired to obtain a salt of the compound of the present invention, if the compound of the present invention is obtained in the form of a salt, it may be purified as it is, and if it is obtained in the free form, it is dissolved in an appropriate organic solvent. Alternatively, it may be suspended and an acid or base may be added to form a salt by a usual method.
- deuterium converter which converts any one or more of the 1 H to 2 H (D) of the compound represented by formula (1), the compound represented by the formula (1) Included.
- the present invention includes a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. Further, since the compound of the present invention may exist in the form of a hydrate and / or a solvate with various solvents (such as an ethanol solvate), these hydrates and / or solvates are also present. Included in the compounds of the invention. Furthermore, the present invention includes all tautomers of compound (1) of the present invention, all existing stereoisomers, and crystalline forms of all modes, as well as mixtures thereof.
- the compounds (1) of the present invention are optical isomers based on optically active centers, atropisomers based on axial or planar chirality generated by the constraint of intramolecular rotation, other steric isomers, and mutual mutations. All possible isomers and mixtures thereof, including these, are included within the scope of the invention, although some may have sexes, geometric isomers and the like.
- the optical isomer and the atrop isomer can be obtained as a racemate, or as an optically active substance when a starting material or an intermediate for optical activity is used.
- the corresponding raw material, intermediate or final racemate is physically separated by a known separation method such as a method using an optically active column or a fractional crystallization method. It can be divided into their optical racemates either or chemically.
- a known separation method such as a method using an optically active column or a fractional crystallization method. It can be divided into their optical racemates either or chemically.
- the diastereomer method two types of diastereomers are formed from a racemate by a reaction using an optically active dividing agent. Since these different diastereomers generally have different physical properties, they can be separated by a known method such as fractional crystallization.
- the compound of the following formula (Ia) can be produced by the following production method. (Wherein, R 2, R 3, Q 1, Q 2, X, Y and Z are the same as defined in claim 1.)
- Compound (Ia) is obtained by an amidation reaction between (IIa) and ammonia.
- the amidation reaction of compound (IIa) can be carried out according to a conventional method. For example, this reaction is accomplished by converting compound (IIa) to a reactive derivative (eg, lower alkyl ester, active ester, acid anhydride, acid halide, etc.) and reacting with ammonia.
- a reactive derivative eg, lower alkyl ester, active ester, acid anhydride, acid halide, etc.
- the active ester include p-nitrophenyl ester, N-hydroxysuccinimide ester, pentafluorophenyl ester and the like.
- the acid anhydride include a mixed acid anhydride with ethyl chlorocarbonate, isobutyl chlorocarbonate, isovaleric acid, pivalic acid and the like.
- Specific examples of the solvent should be selected according to the type of the raw material compound and the like, and examples thereof include THF, dioxane, DME, acetonitrile, DMF, toluene, ethyl acetate, isopropyl acetate and the like, and are used alone or as a mixed solvent. can do.
- the reaction temperature is not particularly limited, but is usually selected from the range from ⁇ 20 ° C. to the boiling point of the solvent used, and is preferably 0 ° C. to 30 ° C.
- the reaction time is usually 30 minutes to 24 hours.
- Compound (Ia) is also produced by reacting compound (IIa) with an ammonium salt such as (NH 4 ) 2 CO 3 in the presence of a condensing agent.
- a condensing agent include N, N'-dicyclohexylcarbodiimide, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide-1 hydrochloride, N, N'-carbonyldiimidazole, and benzotriazole-1-yl.
- -Oxytris (pyrrolidino) phosphonium-hexafluorophosphate and the like can be mentioned.
- condensing agents can be used alone or in combination with these condensing agents and peptide synthesis reagents such as N-hydroxysuccinimide and N-hydroxybenzotriazole.
- Specific examples of the solvent should be selected according to the type of the raw material compound and the like, and examples thereof include THF, dioxane, DME, acetonitrile, DMF, toluene, ethyl acetate, isopropyl acetate and the like, and are used alone or as a mixed solvent. can do.
- the reaction temperature is not particularly limited, but is usually selected from the range from ⁇ 20 ° C. to the boiling point of the solvent used, and is preferably 0 ° C. to 30 ° C.
- the reaction time is usually 30 minutes to 24 hours.
- the compound of the following formula (1b) can be produced by the following production method.
- R 2 , R 3 , Q 1 , Q 2 , X, Y and Z are the same as the definition of Item 1.
- P 1 is a 2,4-dimethoxybenzyl group, a p-methoxybenzyl group, etc.
- a protecting group for nitrogen atoms that can be removed under acidic conditions and P 2 is hydrogen, or a nitrogen atom that can be removed under acidic conditions such as 2,4-dimethoxybenzyl group and p-methoxybenzyl group. Protecting group.
- Compound (Ib) is obtained by deprotecting compound (IIb).
- Deprotection of compound (IIb) can be performed according to a conventional method. For example, this reaction is accomplished by reacting compound (IIb) with an organic strong acid such as trifluoroacetic acid, methanesulfonic acid or trifluoromethanesulfonic acid, or an inorganic strong acid such as hydrochloric acid, sulfuric acid or nitrate.
- an organic strong acid such as trifluoroacetic acid, methanesulfonic acid or trifluoromethanesulfonic acid
- an inorganic strong acid such as hydrochloric acid, sulfuric acid or nitrate.
- Deprotection of compound (IIb) is performed in a solvent or in the absence of a solvent.
- the solvent should be selected according to the type of the starting compound, and examples thereof include toluene, THF, dioxane, DME, dichloromethane, chloroform, ethyl acetate, isopropyl acetate, acetone, acetonitrile, DMF, DMSO and the like. It can be used alone or as a mixed solvent.
- a protecting group for the nitrogen atom in the compound (IIb) a protecting group that cleaves under acidic conditions, such as a t-butoxycarbonyl group, a t-butyl group, and a p-methoxybenzyl group, other than the 2,4-dimethoxybenzyl group.
- the reaction temperature varies depending on the type of the raw material compound used and the like, but is usually about ⁇ 30 ° C. to about 150 ° C., preferably about ⁇ 10 ° C. to about 70 ° C.
- the reaction time is usually 30 minutes to 24 hours.
- the compound of the following formula (1c) can be produced by the following production method. (In the equation, R 4 , R 5 , Q 1 , Q 2 , X, Y, Z and n are the same as the definition in item 1.)
- Compound (Ic) is obtained by methylating compound (IIc).
- Methylation of compound (IIc) can be carried out according to a conventional method. For example, this reaction is accomplished by reacting compound (IIc) with a methylating agent such as methyl iodide, methyl bromide, dimethyl sulfate, etc. in the presence of a base in a suitable solvent.
- a methylating agent such as methyl iodide, methyl bromide, dimethyl sulfate, etc.
- the solvent should be selected according to the type of the raw material compound and the like, and examples thereof include toluene, THF, dioxane, DME, ethyl acetate, isopropyl acetate, acetone, acetonitrile, DMF, NMP and the like, and alone or It can be used as a mixed solvent.
- Specific examples of the base used include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and lithium hydroxide, alkali metal hydrides such as sodium hydride and potassium hydride, t-butoxypotassium, sodium methoxydo and the like.
- Alkali alkali metals such as alkoxy alkali metals, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, and cesium carbonate can be mentioned.
- the reaction temperature varies depending on the type of raw material compound and reagent used, but is usually about ⁇ 30 ° C. to about 150 ° C., preferably about ⁇ 10 ° C. to about 70 ° C.
- the reaction time is usually 30 minutes to 24 hours.
- the compounds of formulas (Ia), (Ib) and (Ic) produced by the above production methods 1, 2 and 3 can be isolated and purified by ordinary methods such as chromatography and recrystallization.
- the raw material compounds used in the above production methods 1, 2 and 3 can be produced by the following methods.
- the compound of the following formula (1c') can also be produced by the following production method. (In the equation, R 4 , R 5 , Q 1 , Q 2 , and n are the same as the definition in item 1.)
- Compound (Ic') is produced by reacting compound (IIc1') with compound (IIc2') in the presence of a condensing agent.
- a condensing agent include N, N'-dicyclohexylcarbodiimide, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide-1 hydrochloride, N, N'-carbonyldiimidazole, benzotriazole-1-yl.
- condensing agents can be used alone or in combination with these condensing agents and peptide synthesis reagents such as N-hydroxysuccinimide and N-hydroxybenzotriazole.
- Specific examples of the solvent should be selected according to the type of the raw material compound and the like, and examples thereof include THF, dioxane, DME, acetonitrile, DMF, toluene, pyridine, ethyl acetate, isopropyl acetate and the like, and are used alone or in a mixed solvent. Can be used as.
- the reaction temperature varies depending on the type of raw material compound and reagent used, but is usually -100 to 200 ° C, preferably -30 to 150 ° C.
- the reaction time is usually 30 minutes to 24 hours.
- the compound (IIa) used in the production method 1 is produced according to the method represented by the following reaction formula. (In the equation, R 2 , R 3 , Q 1 , Q 2 , X, Y and Z are the same as in the definition of item 1, and R is C 1-6 alkyl.)
- Step 1 Compound (IIIa) is obtained by alkylating compound (IVa).
- the alkylation reaction of step 1 can be carried out according to a conventional method. For example, this reaction is carried out by reacting compound (IVa) with an alkyl halide or cycloalkyl halide represented by R 2 X or R 3 X in a suitable solvent in the presence of a base. Further, the compound forming a C 3-6 cycloalkyl or a 4-6 member saturated heterocycle together with the carbon atom to which R 2 and R 3 are bonded corresponds to the compound (IVa) under the above reaction conditions.
- a dihalogen compound for example, X- (CH 2 ) n- X (n represents an integer of 3 to 6 and X represents a halogen
- a dihalogen compound for example, X- (CH 2 ) n- X (n represents an integer of 3 to 6 and X represents a halogen)
- the solvent should be selected according to the type of the raw material compound and the like, and examples thereof include THF, dioxane, DME, acetonitrile, DMF, toluene, ethyl acetate, isopropyl acetate and the like, and are used alone or as a mixed solvent. can do.
- the base used include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and lithium hydroxide, alkali metal hydrides such as sodium hydride and potassium hydride, t-butoxypotassium, sodium methoxydo and the like.
- Alkali metal carbonates such as alkoxy alkali metals, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, and cesium carbonate can be mentioned.
- the reaction temperature varies depending on the type of raw material compound and reagent used, but is usually 0 to 200 ° C, preferably 20 to 150 ° C.
- the reaction time is usually 30 minutes to 24 hours.
- Step 2 Compound (IIa) is obtained by hydrolyzing compound (IIIa).
- the hydrolysis reaction of step 2 can be carried out according to a conventional method. For example, this reaction is carried out by contacting compound (IIIa) with water under acidic or basic conditions in a suitable solvent.
- the solvent should be selected according to the type of the raw material compound and the like, and examples thereof include THF, dioxane, DME, acetone, acetonitrile, DMF, DMSO, methanol, ethanol, isopropanol, water and the like, and alone or It can be used as a mixed solvent.
- Specific examples of the acid used include mineral acids such as hydrochloric acid and sulfuric acid.
- the bases used include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and lithium hydroxide, alkoxy alkali metals such as t-butoxypotassium, sodium carbonate, potassium carbonate and lithium carbonate.
- alkali metal carbonate examples include alkali metal carbonate.
- the reaction temperature varies depending on the type of raw material compound and reagent used, but is usually 0 to 150 ° C, preferably 20 to 100 ° C.
- the reaction time is usually 30 minutes to 24 hours.
- (IIIa') is produced by a condensation dehydration cyclization reaction between the compound (IIIa1) and the compound (IIIa2).
- R 2 , R 3 , Q 1 and Q 2 are the same as the definition of item 1, and R is C 1-6 alkyl.
- the condensation dehydration cyclization reaction of compound (IIIa1) and compound (IIIa2) can be carried out according to a conventional method. For example, this reaction is accomplished by converting compound (IIIa2) to a reactive derivative (eg, lower alkyl ester, active ester, acid anhydride, acid halide, etc.) and reacting with compound (IIIa1).
- a reactive derivative eg, lower alkyl ester, active ester, acid anhydride, acid halide, etc.
- the active ester include p-nitrophenyl ester, N-hydroxysuccinimide ester, pentafluorophenyl ester and the like.
- Specific examples of the acid anhydride include a mixed acid anhydride with ethyl chlorocarbonate, isobutyl chlorocarbonate, isovaleric acid, pivalic acid and the like.
- the solvent should be selected according to the type of the raw material compound and the like, and examples thereof include esters such as THF, dioxane, DME, acetonitrile, DMF, toluene, pyridine or ethyl acetate and isopropyl acetate. Alternatively, it can be used as a mixed solvent.
- the reaction temperature varies depending on the type of raw material compound and reagent used, but is usually -100 to 200 ° C, preferably -30 to 150 ° C.
- the reaction time is usually 30 minutes to 24 hours.
- the compound (IIIa') is also produced by reacting the compound (IIIa1) and the compound (IIIa2) in the presence of a condensing agent.
- a condensing agent include N, N'-dicyclohexylcarbodiimide, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide-1 hydrochloride, N, N'-carbonyldiimidazole, and benzotriazole-1-yl.
- -Oxytris (pyrrolidino) phosphonium-hexafluorophosphate and the like can be mentioned.
- condensing agents can be used alone or in combination with these condensing agents and peptide synthesis reagents such as N-hydroxysuccinimide and N-hydroxybenzotriazole.
- Specific examples of the solvent should be selected according to the type of the raw material compound and the like, and examples thereof include THF, dioxane, DME, acetonitrile, DMF, toluene, pyridine, ethyl acetate, isopropyl acetate and the like, and are used alone or in a mixed solvent. Can be used as.
- the reaction temperature varies depending on the type of raw material compound and reagent used, but is usually -100 to 200 ° C, preferably -30 to 150 ° C.
- the reaction time is usually 30 minutes to 24 hours.
- (IVa') is produced by a condensation dehydration cyclization reaction between the compound (IVa1) and the compound (IVa2).
- Q 1 and Q 2 are the same as the definition of item 1, and R is C 1-6 alkyl.
- Compound (IVa') is produced using compound (IVa1) and compound (IVa2) according to the method described in Production Method 6.
- (IVa ′′) is produced by a condensation dehydration cyclization reaction between the compound (IVa3) and the compound (IVa4).
- Q 1 and Q 2 are the same as the definition of item 1, and R is C 1-6 alkyl.
- Compound (IVa ′′) is produced using compound (IVa3) and compound (IVa4) according to the method described in Production Method 6.
- (IVa''') is produced by a condensation dehydration cyclization reaction between the compound (IVa5) and the compound (IVa6).
- Q 1 and Q 2 are the same as the definition of item 1, and R is C 1-6 alkyl.
- the compound (IVa ′′ ′′) is produced by using the compound (IVa5) and the compound (IVa6) according to the method described in the production method 6.
- a dehydrating agent such as phosphorus oxychloride or a Burgess reagent as an additive.
- the compound (IIb) used in the production method 2 is produced according to the method represented by the following reaction formula.
- R 2 , R 3 , Q 1 , Q 2 , X, Y and Z are the same as the definition of Item 1.
- P 1 is a 2,4-dimethoxybenzyl group, a p-methoxybenzyl group, etc.
- P 2 is hydrogen, or a nitrogen atom that can be removed under acidic conditions such as 2,4-dimethoxybenzyl group and p-methoxybenzyl group. Protecting group.
- Step 1 Compound (IVb) is obtained by reacting compound (Vb) with sodium sulfite.
- the substitution reaction of step 1 can be carried out according to a conventional method. For example, this reaction is carried out by contacting sodium sulfite in a suitable solvent.
- solvents include, but should be selected according to the kinds of starting compounds, for example, Et 2 O, THF, dioxane, and methanol such as DME, ethanol, alcohols such as isopropyl alcohol, toluene or the like Can be used alone or as a mixed solvent.
- the reaction temperature varies depending on the type of raw material compound and reagent used, but is usually ⁇ 100 ° C. to 200 ° C., preferably 0 ° C. to 150 ° C.
- the reaction time is usually 30 minutes to 24 hours.
- Step 2 Compound (IIIb) is obtained by sulfonamided compound (IVb).
- the sulfonamide formation in step 2 can be carried out according to a conventional method. For example, this reaction is accomplished by converting compound (IVb) to a sulfonyl chloride and then reacting with an amine. Conversion to sulfonyl chloride is carried out by the action of phosphorus oxychloride in a solvent or in the absence of a solvent. Examples of solvents include, but should be selected according to the kinds of starting compounds, for example, Et 2 O, THF, dioxane, DME, include toluene, may be used alone or as a mixed solvent.
- the reaction temperature varies depending on the type of raw material compound and reagent used, but is usually ⁇ 100 ° C. to 200 ° C., preferably 0 ° C. to 150 ° C.
- the reaction time is usually 30 minutes to 24 hours.
- the conversion of sulfonyl chloride, an intermediate of step 2, to sulfonamides is a mono or di-substituted amine NHP 1 P 2 with a protecting group that can be removed under acidic conditions in the presence or absence of a base in the solvent. It is done by acting.
- solvents include, but should be selected according to the kinds of starting compounds, for example, Et 2 O, THF, dioxane, DME, DMF, acetonitrile, toluene. Be used alone or in a mixed solvent Can be done.
- the base used include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and lithium hydroxide, alkoxy alkali metals such as t-butoxypotassium, sodium carbonate, potassium carbonate and lithium carbonate.
- examples thereof include organic bases such as alkali metal carbonate, triethylamine, N, N-diisopropylethylamine, pyridine, 2,6-rutidine, 2,4,6-cholidine and 4-dimethylaminopyridine.
- the reaction temperature varies depending on the type of raw material compound and reagent used, but is usually ⁇ 100 ° C. to 200 ° C., preferably 0 ° C. to 150 ° C.
- the reaction time is usually 30 minutes to 24 hours.
- Step 3 Compound (IIb) is obtained by alkylating compound (IIIb). Compound (IIb) is produced using compound (IIIb) according to the method described in Step 5 of Production Method 1.
- (Vb') is produced by a condensation dehydration cyclization reaction between the compound (Vb1) and the compound (Vb2). (Wherein, Q 1 and Q 2 are the same as defined in claim 1.)
- the compound (Vb') is produced by using the compound (Vb1) and the compound (Vb2) according to the method described in the production method 6.
- the compound (Vb ′′) is produced by using the compound (Vb3) and the compound (Vab) according to the method described in the production method 6.
- the compound (Vb ′′ ′′) is produced by using the compound (Vb5) and the compound (Vb6) according to the method described in the production method 9.
- (IIc') is produced by a condensation dehydration cyclization reaction between the compound (IIc1) and the compound (IIc2).
- R 4 , R 5 , Q 1 , Q 2 , and n are the same as the definition in item 1.
- Compound (IIc') is produced using compound (IIc1) and compound (IIc2) according to the method described in Production Method 6.
- (IIc ′′) is produced by a condensation dehydration cyclization reaction between the compound (IIc3) and the compound (IIc4).
- R 4 , R 5 , Q 1 , Q 2 , and n are the same as the definition in item 1.
- Compound (IIc ′′) is produced using compound (IIc3) and compound (IIc4) according to the method described in Production Method 6.
- (IIc''') is produced by a condensation dehydration cyclization reaction between the compound (IIc5) and the compound (IIc6).
- R 4 , R 5 , Q 1 , Q 2 , and n are the same as the definition in item 1.
- Compound (IIc ′′ ′′) is produced using compound (IIc5) and compound (IIc6) according to the method described in Production Method 9.
- the compound of the present invention represented by the formula (1) or an intermediate thereof can be separated and purified by a method known to those skilled in the art.
- extraction, partitioning, reprecipitation, column chromatography (for example, silica gel column chromatography, ion exchange column chromatography or preparative liquid chromatography) or recrystallization can be mentioned.
- the recrystallization solvent include an alcohol solvent such as methanol, ethanol or 2-propanol, an ether solvent such as diethyl ether, an ester solvent such as ethyl acetate, an aromatic hydrocarbon solvent such as benzene or toluene, and acetone.
- a halogen-based solvent such as dichloromethane or chloroform
- a hydrocarbon-based solvent such as hexane
- an aproton solvent such as dimethylformamide or acetonitrile, water, or a mixed solvent thereof and the like
- the method described in Volume 1 of the Experimental Chemistry Course (edited by the Chemical Society of Japan, Maruzen) can be used.
- the molecular structure of the compound of the present invention is determined by a spectroscopic method such as nuclear magnetic resonance method, infrared absorption method, circular dichroism spectrum analysis method, etc., with reference to the structure derived from each raw material compound. And it can be easily done by mass spectrometry.
- the intermediate or final product in the above production method is required to appropriately convert its functional group, and in particular, to extend various side chains from amino, hydroxyl group, carbonyl, halogen and the like, and at that time.
- Functional group conversion and side chain extension can be performed by conventional methods (see, for example, Comprehensive Organic Transformations, R.C. Larock, John Wiley & Sons Inc. (1999), etc.).
- the compound of the present invention represented by the formula (1) or a pharmaceutically acceptable salt thereof may have an asymmetry or may have a substituent having an asymmetric carbon, and such compounds are present.
- the compounds of the present invention also include mixtures and isolated compounds of each of these isomers and can be produced according to conventional methods. Examples of the production method include a method using a raw material having an asymmetric point, or a method of introducing an asymmetry in an intermediate stage.
- the optical isomer can be obtained by using an optically active raw material or performing optical resolution or the like at an appropriate stage in the manufacturing process.
- an optical division method for example, when the compound represented by the formula (1) or an intermediate thereof has a basic functional group, it is contained in an inert solvent (for example, an alcohol solvent such as methanol, ethanol, 2-propanol or the like). , Ether solvent such as diethyl ether, ester solvent such as ethyl acetate, hydrocarbon solvent such as toluene, aproton solvent such as acetonitrile, or a mixed solvent of two or more kinds selected from the above solvents), optically active Acids (for example, monocarboxylic acids such as mandelic acid, N-benzyloxyalanine and lactic acid, tartrate acids, dicarboxylic acids such as o-diisopropyridene tartrate and malic acid, sulfonic acids such as camphor sulfonic acid and bromo camphor sulfonic acid).
- an inert solvent for example, an alcohol solvent such as methanol, ethanol, 2-propanol
- a diastereomer method in which a salt is formed using a solvent can be mentioned.
- an optically active amine for example, 1-phenylethylamine, quinine, quinidine, cinchonidine, cinchonine, etc.
- Optical resolution can also be performed by forming a salt using an organic amine such as strikinine).
- the temperature at which the salt is formed is selected from the range from ⁇ 50 ° C. to the boiling point of the solvent, preferably the range from 0 ° C. to the boiling point, and more preferably the range from room temperature to the boiling point of the solvent. In order to improve the optical purity, it is desirable to raise the temperature to near the boiling point of the solvent. When the precipitated salt is collected by filtration, it can be cooled if necessary to improve the yield.
- the amount of the optically active acid or amine used is appropriately in the range of about 0.5 to about 2.0 equivalents, preferably about 1 equivalent with respect to the substrate.
- the crystals are placed in an inert solvent (for example, an alcohol solvent such as methanol, ethanol, 2-propanol; an ether solvent such as diethyl ether; an ester solvent such as ethyl acetate; a hydrocarbon solvent such as toluene; acetonitrile. It can also be recrystallized in an aproton solvent such as (or a mixed solvent of two or more kinds selected from the above solvents) to obtain a highly pure optically active salt. Further, if necessary, the optically resolved salt can be treated with an acid or a base by a usual method to obtain a free form.
- an inert solvent for example, an alcohol solvent such as methanol, ethanol, 2-propanol; an ether solvent such as diethyl ether; an ester solvent such as ethyl acetate; a hydrocarbon solvent such as toluene; acetonitrile.
- an aproton solvent such as (or a mixed solvent
- novel oxadiazole derivative of the present invention Since the novel oxadiazole derivative of the present invention has anticonvulsant activity and GABA-A receptor activating action (GABA nervous system activating action), it is a therapeutic agent and / or a therapeutic agent for diseases associated with GABA nervous system dysfunction. Can be a preventative agent.
- the novel oxadiazole derivative of the present invention has a GABA-A receptor activating action and / or an action of strengthening inhibition (I) in the balance between excitement (E) and inhibition (I) (E / I balance). Since it has, it can be a therapeutic agent and / or a preventive agent for nervous system diseases or psychiatric disorders.
- Epilepsy eg, epilepsy (eg, tonic, interstitial, deficient, myochrony, generalized, including weakness, focal, unclassified), epilepsy, epilepsy, as a neurological or mental illness. Waist Syndrome, Drave Syndrome, Lennox-Gasteau Syndrome, Autosomal Dominant Nocturnal Frontal Epilepsy (ADNFLE), Medial Temporal Epilepsy with Kaiba Sclerosis as a Clear Specific Symptom Group, Rasmussen Syndrome, etc.), Neuropathic Pain, Developmental disorders, autism, bipolar disorder, schizophrenia, Alzheimer's disease and other dementia, muscular atrophic lateral sclerosis, Parkinson's disease, depressive symptoms with or without epilepsy, anxiety, compulsive disorder, Parkinson Disease ⁇ Rem sleep disorder associated with Levy body dementia can be mentioned.
- epilepsy eg, tonic, interstitial, deficient, myochrony, generalized, including weakness, focal, unclassified
- epilepsy epilepsy
- epilepsy epile
- the novel oxadiazole derivatives of the present invention are preferably epilepsy (epileptic seizures (tonic seizures, interstitial seizures, deficiency seizures, myochrony seizures, generalized seizures including weakness seizures, focal epilepsy, unclassified seizures), epileptic epilepsy. , West Syndrome, Dravet Syndrome, Lennox-Gasteau Syndrome, Autosomal Dominant Nocturnal Frontal Epilepsy (ADNFLE), Medial Temporal Epilepsy with Kaiba Sclerosis as a Clear Specific Symptom Group, Rasmussen Syndrome, etc.) Or it can be a prophylactic agent.
- epilepsy epileptic seizures (tonic seizures, interstitial seizures, deficiency seizures, myochrony seizures, generalized seizures including weakness seizures, focal epilepsy, unclassified seizures
- epileptic epilepsy epileptic seizures (tonic seizures, interstitial seizures, deficiency seizures, myochrony seizures, generalized seizures including weakness seizures, focal epilepsy, un
- prevention is an act of administering the active ingredient of the present invention to a healthy person who has not developed a disease, for example, for the purpose of preventing the onset of a disease. be.
- Treatment is an act of administering the active ingredient of the present invention to a person (patient) who has been diagnosed as having a disease by a doctor. The act of taking a patient suffering from such a disease to control a seizure associated with the disease also falls under “prevention” or "treatment” here.
- the novel oxadiazole derivative of the present invention has a GABA-A receptor activating action and / or an action of strengthening inhibition (I) in the balance between excitement (E) and inhibition (I) (E / I balance). Therefore, it can be a therapeutic agent and / or a preventive agent for nervous system diseases or psychiatric disorders.
- the novel oxadiazole derivative of the present invention can be a therapeutic agent and / or a preventive agent for a disease in which excitement (E) in the E / I balance is enhanced and / or suppression (I) is decreased.
- Neurological or psychiatric disorders include epilepsy, neuropathy pain, neurodevelopmental disorders, bipolar disorders and related disorders, schizophrenia spectrum disorders, Alzheimer's disease and other neurocognitive disorders, and muscle atrophic lateral cord sclerosis.
- Diseases Parkinson's disease, depressive syndrome, anxiety group, compulsive disorder, trauma and stress-related disorders, sleep-wake disorder group, and / or REM sleep disorder associated with Parkinson's disease / Lewy body dementias. ..
- the novel oxadiazole derivative of the present invention has anticonvulsant activity and GABA-A receptor activating action (GABA nervous system activating action), it is a therapeutic agent for diseases associated with GABA nervous system dysfunction and / Or it can be a preventive agent.
- Diseases associated with GABA nervous system dysfunction include epilepsy, neuropathy pain, neurodevelopmental disorders, bipolar disorders and related disorders, schizophrenia spectrum disorders, Alzheimer's disease and other neurocognitive disorders, and muscle atrophy. Lateral sclerosis, Parkinson's disease, depressive syndrome, anxiety group, compulsive disorder, trauma and stress-related disorders, sleep-wake disorder group, and / or REM sleep disorder associated with Parkinson's disease / Lewy body dementias Can be mentioned.
- epilepsy examples include epileptic seizures (tonic seizures, interstitial seizures, deficiency seizures, myochrony seizures, generalized seizures including weakness seizures, focal epilepsy, and unclassified seizures), epilepsy stacking, waist syndrome, and Dravet syndrome.
- Lennox-Gasteau syndrome autosomal dominant nocturnal frontal epilepsy (ADNFLE), Angelman syndrome, nodular sclerosis, medial temporal lobe epilepsy with hippocampal sclerosis as a distinct group of specific symptoms, and / or Rasmussen syndrome Can be mentioned.
- it can be preferably used for Dravet syndrome, Lennox-Gastaut syndrome and / or Angelman syndrome.
- the depressive syndrome includes, for example, a depressive disorder group with anxiety pain, a depressive disorder group with mixed characteristics, a depressive disorder group with melancholia characteristics, a depressive disorder group with atypical characteristics, and mood-matching.
- Depressive disorder group with psychotic traits depressive disorder group with psychotic traits that do not match mood, depressive disorder group with tension disease, perinatal onset, seasonal depressive disorder group, severe mood dysregulation, Depression / major depressive disorder, persistent depressive disorder, premenopausal discomfort disorder, substance / drug-induced depressive disorder, depressive disorder due to other medical disorders, other identified depressive disorders, and / or unspecified Depressive disorder and so on.
- it can be preferably used for depression / major depressive disorder.
- Examples of the anxiety group include segregation anxiety, selective silence, localized anxiety, social anxiety, panic disorder, panic attack, open space anxiety, general anxiety, substance / drug-induced anxiety, and others. Anxiety due to medical disorders, other identified anxiety, and / or unspecified anxiety.
- the bipolar disorder and related disorder groups include, for example, bipolar I disorder, bipolar II disorder, cyclothymia, substance / drug-induced bipolar disorder and related disorders, bipolar disorder due to other medical diseases, and Included are related disorders, other identified bipolar and related disorders, and / or unspecified bipolar and related disorders. These further include depressive, depressive or anxious symptoms associated with said bipolar disorder and related disorder groups.
- prevention is an act of administering the active ingredient of the present invention to a healthy person who has not developed a disease, for example, for the purpose of preventing the onset of a disease. be.
- Treatment is an act of administering the active ingredient of the present invention to a person (patient) who has been diagnosed as having a disease by a doctor. The act of taking a patient suffering from such a disease to control a seizure associated with the disease also falls under “prevention” or "treatment” here.
- the administration route of the compound of the present invention may be oral administration, parenteral administration or rectal administration, and the daily dose thereof varies depending on the type of compound, administration method, patient's symptom / age and the like.
- oral administration usually about 0.01 to 1000 mg, more preferably about 0.1 to 500 mg per kg body weight of a human or mammal can be administered in one to several divided doses.
- parenteral administration such as intravenous injection, for example, about 0.01 mg to 300 mg, more preferably about 1 mg to 100 mg per 1 kg body weight of a human or mammal can be administered.
- the compound of the present invention can be formulated and administered directly or by using an appropriate dosage form by oral administration or parenteral administration.
- Dosage forms include, but are not limited to, tablets, capsules, powders, granules, liquids, suspensions, injections, patches, poultices and the like.
- the pharmaceutical product is produced by a known method using pharmaceutically acceptable additives. Additives include excipients, disintegrants, binders, fluidizers, lubricants, coatings, solubilizers, solubilizers, thickeners, dispersants, stabilizers, and sweeteners, depending on the purpose. , Perfume and the like can be used.
- lactose mannitol, crystalline cellulose, low-substituted hydroxypropyl cellulose, corn starch, partially pregelatinized starch, carmellose calcium, croscarmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, stearer.
- examples thereof include magnesium acid, stearyl sodium fumarate, polyethylene glycol, propylene glycol, titanium oxide, and talc.
- the compound of the present invention can be used in combination with at least one drug classified as an antiepileptic drug, an antidepressant drug, or an antipsychotic drug.
- the combined use is a form of administration as a preparation prepared separately from the compound of the present invention, and may be administered to the administration subject at the same time as the preparation containing the compound of the present invention, or with a time lag. May be administered after.
- Drugs classified as antiepileptic drugs include, for example, phenytoin that inhibits sodium channels, valproic acid, carbamazepine, lamotrigine, topiramate, etc., etoscusmid that inhibits calcium channels, zonisamide, etc.
- Examples thereof include benzodiazepine-based drugs (diazepam, chronazepam, clovasam, etc.) that enhance the function of the nervous system, valbital-based drugs (phenobarbital, etc.), gabapentin, vigabatrin, and the like.
- Drugs classified as antidepressants include, for example, fluoxetine called SSRI, fluboxamine, paroxetin, sertraline, citaloplum, etc., SNRI called duroxetine, milnacipran, etc., imipramine called tricyclic antidepressant, amitriptyline, chromipramine, etc. , Amoxapine and the like.
- Examples of the drug classified as an antipsychotic drug include haloperidol, spiperon, chlorpromazine and the like, which are typical antipsychotic drugs, and risperidone, quetiapine, olanzapine, clozapine, perospirone, alipiprazole and the like, which are called SDA.
- s is a single line
- d is a double line
- dd is a double line
- t is a triple line
- td is a triple line double line
- q is a quadruple line
- m is a multiple line
- br is a wide range
- brs is a wide single line
- brm is a wide multiple line
- J means a coupling constant
- Reference example 16 Using the corresponding raw material compound, the compound of Reference Example 16 was obtained by reacting and treating in the same manner as in the method described in Reference Example 15.
- Reference Example 17 Ethyl 2- [5- (4-chlorophenyl) -1,2,4-oxadiazole-3-yl] -2-methylpropanoate
- Cesium carbonate (7.82 g) and iodomethane (1.12 ml) were added to a solution of the compound (1.60 g) of Reference Example 12 in DMF (16 ml), and the mixture was stirred overnight at room temperature.
- Reference Example 22 2- [3- (4-chlorophenyl) -1,2,4-oxadiazole-5-yl] -2-methylpropanoic acid A 5 mL / L sodium hydroxide aqueous solution (7.3 ml) was added to a solution of the compound (3.10 g) of Reference Example 3 in methanol (20 ml), and the mixture was heated under reflux for 6 hours. After cooling to room temperature, a 10% aqueous citric acid solution was added to adjust the pH to 4, and the mixture was extracted with ethyl acetate.
- Reference Example 46 1- [3- (4-Bromophenyl) -1,2,4-oxadiazole-5-yl] -N, N-bis (2,4-dimethoxybenzyl) methanesulfonamide Phosphoryl oxychloride (22.5 ml) was added to the compound (1.68 g) of Reference Example 38, and the mixture was heated under reflux for 5 hours and then concentrated under reduced pressure. The residue is added to THF (20 ml), which is a solution of bis (2,4-dimethoxybenzyl) amine (1.56 g), triethylamine (2.75 ml), 4-dimethylaminopyridine (0.06 g) in THF (20 ml).
- Reference Example 54 2- [3- (4-Bromophenyl) -1,2,4-oxazole-5-yl] -N, N-bis (2,4-dimethoxybenzyl) propan-2-sulfonamide
- Cesium carbonate (527 mg) and iodomethane (0.075 ml) were added to a solution of the compound (250 mg) of Reference Example 46 in DMF (5 ml), and the mixture was stirred overnight at room temperature. Water was added to the reaction solution, the mixture was extracted with ethyl acetate, the organic layer was washed with saturated brine, and dried over anhydrous sodium sulfate.
- Example 1 2- [3- (4-fluorophenyl) -1,2,4-oxadiazole-5-yl] -2-methylpropanamide
- the compound (280 mg) obtained in Reference Example 23 and oxalyl chloride (0.384 ml) were dissolved in dehydrated chloroform (10 ml), 2 drops of DMF were added, and the mixture was stirred at room temperature for 1 hour.
- the reaction solution was concentrated under reduced pressure, the residue was dissolved in dehydrated THF (5 ml), a 28% aqueous ammonia solution (1 ml) was added, and the mixture was stirred overnight at room temperature.
- Example 2-16 Reactions and treatments were carried out in the same manner as in Example 1 using the corresponding raw material compounds to obtain the compounds shown in Table 9.
- Example 17 2- [3- (4-fluorophenyl) -1,2,4-oxadiazole-5-yl] propan-2-sulfonamide Trifluoroacetic acid (10 ml) was added to a toluene (20 ml) solution of the compound obtained in Reference Example 55, and the mixture was stirred at room temperature for 15 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane: ethyl acetate; 1: 1) to obtain the compound of Example 17 (103 mg) as a solid.
- Example 18-24 Reactions and treatments were carried out in the same manner as in Example 18 using the corresponding raw material compounds to obtain the compounds shown in Table 10.
- Example 25 5- [3- (4-fluorophenyl) -1,2,4-oxadiazole-5-yl] -1-methylpyrrolidine-2-one Cesium carbonate (0.988 mg) was added to a solution of the compound (500 mg) obtained in Reference Example 62 and methyl iodide (0.19 ml) in DMF (4 ml), and the mixture was stirred at room temperature for 2.5 hours. A 10% aqueous citric acid solution was added to the reaction solution, the mixture was extracted with ethyl acetate, the organic layer was washed with saturated brine, and dried over anhydrous sodium sulfate.
- Examples 26-31 Reactions and treatments were carried out in the same manner as in Example 25 using the corresponding raw material compounds to obtain the compounds shown in Table 11.
- Examples 31 and 32 (S) -5- [3- (4-fluorophenyl) -1,2,4-oxadiazole-5-yl] -1-methylpyrrolidine-2-one and (R)- 5- [3- (4-fluorophenyl) -1,2,4-oxadiazole-5-yl] -1-methylpyrrolidine-2-one
- the compound of Example 25 was separated by a column manufactured by Daicel Corporation (CHIRALPAK TM AD-H (mobile phase: 100% MeCN)) to obtain a pre-peak (enantiomer A) and a post-peak (enantiomer B).
- Example 31 (Enantiomer A): Retention time 4.78 minutes Chiral HPLC (Chiralpak TM AD-H, 0.46 cm ID x 25 cm L, mobile phase: 100% MeCN, flow rate: 1.0 ml / min, temperature: 40 ° C., wavelength: 237 nm)
- Example 32 (Enantiomer B): Retention time 5.99 minutes Chiral HPLC (Chiralpak TM AD-H, 0.46 cm ID x 25 cm L, mobile phase: 100% MeCN, flow rate: 1.0 ml / min, temperature: 40 ° C., wavelength: 237 nm)
- Example 33 (S) -5- [3- (4-fluorophenyl) -1,2,4-oxadiazole-5-yl] -1-methylpyrrolidine-2-one
- the compound of Example 31 can also be produced by the following method.
- 4-fluorobenzamidexim 840 g
- (S) -2-pyrrolidone-5-carboxylic acid (1.08 kg)
- a 50% ethyl acetate solution of propanephosphonic acid anhydride (4.48 kg) was added, and the mixture was stirred at room temperature for 1.5 hours and then at 75 ° C. for 2.5 hours.
- N-heptane (3.02 kg) was added dropwise to the resulting slurry, crystals were collected by filtration, washed with a 40% ethyl acetate / heptane mixed solvent (1.68 kg), and vacuum dried at 40 ° C. to obtain crude crystals (crude crystals (3.02 kg). 1.14 g) was obtained as a light brown solid.
- the crude crystals (1.00 kg) were dissolved in 2-propanol / water (50%, 1.6 kg), 60 g of activated carbon was added, and the mixture was stirred at 25 ° C., and the activated carbon was removed by filtration.
- the filtrate was diluted with 2-propanol / water (50%) to 3.0 kg and added dropwise to water (6.0 L) at 0 ° C. with stirring.
- the crystals were collected by filtration, washed with a 2-propanol / water mixed solvent (12.5%, 2.0 kg), and vacuum dried at 40 ° C. to obtain the compound of Example 33 (944 g) as a white solid. ..
- NMR and HPLC it was confirmed that this compound was the same as the compound of Example 31.
- Test Example 1 Subcutaneous injection pentetrazole model (minimum convulsions model, scPTZ) evaluation
- Subcutaneous injection pen tetrazole model minimum convulsions model, scPTZ
- This study used an animal model, which is a phenotype of generalized absence seizures and myoclonic seizures.
- test compound was orally administered to ddY male mice (obtained from Nippon SLC Co., Ltd., 5 animals in a group, body weight 20 to 30 g), and 1 hour later, pentetrazole 85 mg / kg was subcutaneously administered. Then, the presence or absence of clonic convulsions was observed for 30 minutes. As a control, a 0.5% methylcellulose solution was administered as a test compound, and the same test was performed. The results are shown in Table 12 below. Of the 5 animals, the number was expressed as the number of animals that showed suppression of the onset of convulsions. The test was established when 4 out of 5 animals developed convulsions.
- the compound of the present invention showed an anticonvulsant effect in the evaluation of the subcutaneous injection pentetrazole model (minimum convulsive model, scPTZ) by oral administration.
- the compounds of Examples 11, 16, 25, 28, 30 and 31 showed anticonvulsant activity in more than half of the cases even after oral administration of 25 mg / kg.
- Test Example 2 Rotor Rod Evaluation This test is a test to evaluate the coordinated motor ability inhibitory effect of a drug.
- the rotor rod is a device that rotates a cylindrical rod having a diameter of 4 cm. A mouse is walked on the rotated rod, and the cooperative motility is evaluated using the walking ability as an index.
- Slc A dddy male mouse (obtained from Nippon SLC Co., Ltd., weighing 20 to 30 g) was trained to walk for 5 minutes on a rotor rod device rotated at 12 rpm 3 hours before the test. And only walkable mice are used in the test.
- the test compound was orally administered to 5 animals in a group, and one hour later, the test compound was placed on a rotor rod device rotated at 15 times / minute, and the walking state was observed for 180 seconds to measure the walking time.
- a 0.5% methylcellulose solution was administered as a test compound, and the same test was performed. Coordination ability was expressed by the average value of walking time (seconds) of 5 animals. The results are shown in Table 13. The control was able to walk for 180 seconds.
- any of the examples walking could be continued for 180 seconds without falling from the rotor rod device by oral administration of 25 mg / kg or more, and the coordinated motor ability was not affected. Therefore, the compound of the example in which the subcutaneous injection pentetrazole model (minimum convulsive model, scPTZ) was evaluated in Test Example 1 showed an anticonvulsant effect as described above, but at the dose at which the effect was obtained, the cooperative motor ability was obtained. It was confirmed that there was almost no effect on.
- the subcutaneous injection pentetrazole model minimum convulsive model, scPTZ
- Test Example 3 Evaluation of Febrile Seizure in Drave Model Mouse This test is a test to evaluate the anticonvulsant effect of a drug on febrile seizure in Drave model mouse.
- BALB / c-Scn1a ⁇ +/-> mice (catalog number: RBRC06422; can be provided by the National BioResource Center, RIKEN, through the National BioResource Project of the Ministry of Education, Culture, Sports, Science and Technology).
- This model mouse has a mutation in Scn1A, which is the causative gene of Dravet syndrome patients, and exhibits a pathological condition similar to febrile convulsions due to increased body temperature, which is a symptom of Dravet syndrome patients.
- the test compound was orally administered to male Drave model mice (5 to 8 mice in a group, body weight 20 to 30 g), and 50 minutes later, they were placed in a chamber immersed in a hot water bath to induce an increase in body temperature, and the onset of febrile convulsions was observed. After the onset of febrile convulsions, the rectal body temperature was measured quickly and used as the convulsive threshold body temperature. As a control, a 0.5% methylcellulose solution was administered as a test compound, and the same test was performed. The anticonvulsant activity was expressed as the difference between the drug dose that significantly increased the convulsive threshold body temperature as compared with the control group and the convulsive threshold body temperature with the control group. The results are shown in Table 14.
- the compounds of the present invention showed an effect of increasing the convulsive threshold body temperature of Dravet febrile convulsions, and were shown to have an anticonvulsant effect on the Dravet model.
- the compounds of all the examples showed an anticonvulsant effect on the drave model at a dose that did not affect the coordination disorder.
- Test Example 4 Evaluation of GABA-A receptor activating effect This test is for GABA-A receptor-expressing cells that can be obtained by the method described in the guideline for creating stable cell lines (Lonza Japan website; Non-Patent Document 4). Is a test for evaluating the GABA-A receptor activating effect of a drug using the current induced by GABA as an index. GABA-A receptor-expressing cells were subjected to electrophysiological experiments, and the current observed when 2 ⁇ M GABA solution and subsequently a mixture of 2 ⁇ M GABA and the test compound were added was measured.
- GABA activating activity is indicated by the rate of increase of the current observed when a mixture of 2 ⁇ M GABA and the test compound is added with respect to the current observed only with GABA, and the concentration of the test compound that increases the current by 20% is EC20. It was represented by. Similarly, the current observed when 10 ⁇ M flumazenil mixture was added to 2 ⁇ M GABA and the test compound was measured, and the inhibition rate by flumazenil against the increase in current in the absence of flumazenil was calculated. The results are shown in Table 15.
- the compounds of the present invention showed GABA-A receptor activating activity.
- Flumazenil a benzodiazepine antagonist, strongly inhibits the GABA-A receptor activating activity of clovasam and diazepam, which are classified as benzodiazepines, but unlike that, the GABA-A receptor activating activity of the compound of the present invention is , Flumazenil weakly inhibits the increase in current, indicating that the GABA-A receptor activating activity of the compound of the present invention occurs by a mechanism different from that of benzodiazepines.
- Test Example 5 Evaluation of rat forced swimming model This test is a test for evaluating the antidepressant effect of a drug. When a rat is placed in an inescapable aquarium and allowed to swim, akinesia is observed after the escape behavior. When the rat is placed in the aquarium again the next day, akinesia appears earlier than the first time. This is a method for evaluating the antidepressant effect of a test compound by using the duration of this immobility time as a depressive behavior. Wister male rats (obtained from Charles River Laboratories, Japan, weighing 260-300 g) were allowed to swim in a water tank for 15 minutes the day before the test.
- test compound On the day of the test, the test compound was orally administered (10 to 12 animals in a group), and 1 hour later, the animals were allowed to swim again in the aquarium for 5 minutes to measure the immobility time.
- control group a 0.5% methylcellulose solution was administered as a test compound, and the same test was performed.
- Antidepressant activity was expressed as the average rate of decrease in immobility time relative to the control group. The results are shown in Table 16.
- diazepam has a GABA-A receptor activating effect similar to the compound of the present invention as shown in Experimental Example 4, but did not show an antidepressant effect in a rat forced swimming model.
- Diazepam is one of the benzodiazepines that is also used as an anticonvulsant.
- the fact that the compound of the present invention showed an effect on a model showing no effect on benzodiazepines means that the mechanism of action of GABA-A receptor activation of the compound of the present invention is benzodiazepine.
- the compound of the present invention exhibited an antidepressant effect not found in benzodiazepines due to some unknown mechanism of action. From this, it was suggested that the compound of the present invention has a therapeutic / preventive effect not only for epileptic seizures but also for depressive symptoms that occur at a high rate in epileptic patients.
- the compound of the present invention showed a strong anticonvulsant effect in the evaluation of the subcutaneous injection pentetrazole model (minimum convulsive model, scPTZ).
- minimum convulsive model scPTZ
- Dravet syndrome model mice which are known as one of the intractable generalized epilepsy and whose causative mutation gene has been identified, the convulsive onset threshold body temperature of febrile convulsions was increased at a dose that did not affect the coordinated motor function. ..
- the compounds of the present invention can be used for antiepileptic drugs (tonic seizures, interstitial seizures, deficiency seizures, myochrony seizures, generalized seizures including weakness seizures, focal epilepsy, unclassified seizures, and intractable seizures for which drug treatment has not yet been successful. It is useful as a therapeutic and / or prophylactic for generalized seizures such as classified Dravet syndrome, West syndrome and Lennox-Gasteau syndrome. Since the compound of the present invention also has GABA-A receptor activating activity, anxiety groups, obsessive disorders, Parkinson's disease / Lewy body dementias, which are recognized to have therapeutic effects by existing GABA nervous system activators. It is also useful as a therapeutic and / or prophylactic for REM sleep disorders associated with.
- the GABA-A receptor activating activity of the compound of the present invention is exhibited in a mode of action different from that of benzodiazepine, which is one of the existing GABA nervous system activators, and a rat forced swimming model showing no effect with benzodiazepine. Since it was effective against depressive symptoms, it has an effect on depressive symptoms that may or may not occur with epilepsy, and is useful as a therapeutic and / or preventive drug for depressive syndrome, etc., as well as existing antiepileptic drugs. There is no usefulness.
- the compound of the present invention Since the compound of the present invention has a strong anticonvulsant action and also has a GABA-A receptor activating action, it is useful as a therapeutic agent and / or a preventive agent for diseases associated with GABA nervous system dysfunction. be. Further, since the compound of the present invention has an action of strengthening inhibition (I) in the balance (E / I balance) of excitement (E) and inhibition (I), E in the E / I balance is enhanced and / Or is useful as a therapeutic and / or prophylactic agent for diseases with reduced I.
Abstract
Description
てんかんは、脳神経細胞の過剰興奮が原因で発作を呈するが、興奮性神経が強く働く、または抑制性神経の力が弱まる、つまり興奮(E)と抑制(I)のバランス(E/Iバランス)の異常が原因であると考えられている。てんかん以外にも、E/Iバランス異常による疾患が知られている。抑制性神経を賦活化するGABA神経系賦活薬は、不安症、強迫性障害、パーキンソン病・レビー小体型認知症に伴うレム睡眠障害に対する治療効果が示されている。また、E/Iバランス異常は、神経障害性疼痛、発達障害、自閉症、双極性障害、統合失調症、アルツハイマー病やその他認知症、筋萎縮性側索硬化症、パーキンソン病などにも関与することが知られている。事実、E/Iバランス異常を改善する抗てんかん薬の一部は、これら他疾患に広く適用されてきた。しかし、これらてんかん以外の疾患における薬効強度も限定的であり、副作用、薬物動態面の課題も残されている。したがって、新たな薬効・副作用プロファイルを持った抗てんかん薬は、これら多くの精神・神経系疾患にも適用できる可能性があり、開発の意義は大きい。
Q1はハロゲンを表し、
Q2は水素、ハロゲン、シアノ、C1-3アルキル(該アルキルはハロゲン、水酸基、C3-6シクロアルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)又はC1-3アルコキシ(該アルコキシはハロゲン、水酸基、C3-6シクロアルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を表し、
X、Y及びZは、同一又は異なって、窒素原子又は酸素原子を表し、ただし、X、Y及びZを含む環は、X、Y及びZのうちの2つが窒素原子であり、残りの1つが酸素原子であるヘテロアリールであり、
R1は以下の(2)~(4)のいずれかを表し、
R4及びR5は、同一又は異なって、水素、ハロゲン、水酸基、C1-6アルキル(該アルキルはハロゲン、水酸基、C3-6シクロアルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)、又はC3-6シクロアルキル(該シクロアルキルはハロゲン、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を表すか、あるいは、R4及びR5が同一の炭素原子上又は隣接する炭素原子上に存在する場合、それらが結合する炭素原子と一緒になってC3-6シクロアルキル(該シクロアルキルはハロゲン、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)又は窒素原子及び酸素原子からなる群から独立して選択される1または2個のヘテロ原子を含むC4-6飽和複素環(該飽和複素環はハロゲン、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基を形成してもよく、
nは、0~2の整数を表す。]
項1に記載の化合物又はその製薬学的に許容される塩。
項2に記載の化合物又はその製薬学的に許容される塩。
項1~3のいずれか一項に記載の化合物又はその製薬学的に許容される塩。
項4に記載の化合物又はその製薬学的に許容される塩。
Q2が水素、フッ素、塩素、臭素、シアノ、C1-3アルキル(該アルキルはフッ素で置換されていてもよい)又はC1-3アルコキシ(該アルコキシはフッ素で置換されていてもよい)である、
項1~5のいずれか一項に記載の化合物又はその製薬学的に許容される塩。
2-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-2-メチルプロパンアミド(実施例1)、
2-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]-2-メチルプロパンアミド(実施例2)、
2-[3-(4-ブロモフェニル)-1,2,4-オキサジアゾール-5-イル]-2-メチルプロパンアミド(実施例3)、
1-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]シクロプロパン-1-カルボキサミド(実施例4)、
1-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]シクロプロパン-1-カルボキサミド(実施例5)、
1-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]-3-フルオロシクロブタン-1-カルボキサミド(実施例6)、
1-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]-3,3-ジフルオロシクロブタン-1-カルボキサミド(実施例7)、
1-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]シクロブタン-1-カルボキサミド(実施例8)、
1-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]シクロペンタン-1-カルボキサミド(実施例9)、
4-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]テトラヒドロ-2H-ピラン-4-カルボキサミド(実施例10)、
2-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]-2-エチルブタンアミド(実施例11)、
2-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]-2-メチルプロパンアミド(実施例12)、
2-[5-(4-クロロフェニル)-1,2,4-オキサジアゾール-3-イル]-2-メチルプロパンアミド(実施例13)、
2-[5-(4-ブロモフェニル)-1,2,4-オキサジアゾール-3-イル]-2-メチルプロパンアミド(実施例14)、
2-[5-(4-クロロフェニル)-1,3,4-オキサジアゾール-2-イル]-2-メチルプロパンアミド(実施例15)、
2-[5-(4-ブロモフェニル)-1,3,4-オキサジアゾール-2-イル]-2-メチルプロパンアミド(実施例16)、
2-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]プロパン-2-スルホンアミド(実施例17)、
2-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]プロパン-2-スルホンアミド(実施例18)、
2-[3-(4-ブロモフェニル)-1,2,4-オキサジアゾール-5-イル]プロパン-2-スルホンアミド(実施例19)、
2-[5-(4-クロロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-スルホンアミド(実施例20)、
2-[5-(4-ブロモフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-スルホンアミド(実施例21)、
2-[5-(4-フルオロフェニル)-1,3,4-オキサジアゾール-2-イル]プロパン-2-スルホンアミド(実施例22)、
2-[5-(4-クロロフェニル)-1,3,4-オキサジアゾール-2-イル]プロパン-2-スルホンアミド(実施例23)、
2-[5-(4-ブロモフェニル)-1,3,4-オキサジアゾール-2-イル]プロパン-2-スルホンアミド(実施例24)、
5-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン(実施例25)、
5-[3-(2,4-ジフルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン(実施例26)、
5-[3-(3,4-ジフルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン(実施例27)、
5-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1,5-ジメチルピロリジン-2-オン(実施例28)、
5-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン(実施例29)、
5-[3-(4-ブロモフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン(実施例30)、
(S)-5-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン(実施例31)、及び
(R)-5-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン(実施例32)。
2-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]-2-メチルプロパンアミド(実施例2)、
2-[3-(4-ブロモフェニル)-1,2,4-オキサジアゾール-5-イル]-2-メチルプロパンアミド(実施例3)、
2-[5-(4-クロロフェニル)-1,2,4-オキサジアゾール-3-イル]-2-メチルプロパンアミド(実施例13)、
2-[5-(4-クロロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-スルホンアミド(実施例20)、
5-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン(実施例25)、
5-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン(実施例29)、
(S)-5-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン(実施例31)、及び
(R)-5-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン(実施例32)。
また、本発明の化合物は、興奮(E)と抑制(I)のバランス(E/Iバランス)における抑制(I)を強める作用を有することから、神経系疾患又は精神疾患の治療剤及び/又は予防剤、特に、E/Iバランスにおける興奮(E)が亢進している及び/又は抑制(I)が低下している疾患の治療剤及び/又は予防剤となり得る。
(1)C1-3アルキル(該アルキルはフッ素、水酸基、及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)、であるか、あるいは、
(2)R2及びR3が結合する炭素原子と一緒になってC3-6シクロアルキル(該シクロアルキルはフッ素、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基、または
(3)R2及びR3が結合する炭素原子と一緒になって、窒素原子及び酸素原子からなる群から独立して選択される1または2個のヘテロ原子を含むC4-6飽和複素環(該シクロアルキルはフッ素、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基
が挙げられる。
(1)C1-3アルキル(該アルキルはフッ素で置換されていてもよい)であるか、あるいは、
(2)それらが結合する炭素原子と一緒になってC3-6シクロアルキル(該シクロアルキルはフッ素で置換されていてもよい)を構成した基、または
(3)窒素原子及び酸素原子からなる群から独立して選択される1または2個のヘテロ原子を含むC4-6飽和複素環(該飽和複素環はフッ素で置換されていてもよい)を構成した基
が挙げられる。
(1)水素、
(2)フッ素、
(3)水酸基、
(4)C1-3アルキル(該アルキルはフッ素、水酸基、及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)、
(5)C3-6シクロアルキル(該シクロアルキルはフッ素、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)であるか、あるいは、
R4及びR5が結合する炭素原子上または隣接する炭素原子上に存在する場合、
(6)それらが結合する炭素原子と一緒になってC3-6シクロアルキル(該シクロアルキルはフッ素、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基、または
(7)それらが結合する炭素原子と一緒になってC4-6飽和複素環(該シクロアルキルはフッ素、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基を形成してもよい場合
が挙げられる。なお、ここで「隣接する炭素原子」とは、R4とR5がそれぞれ結合している環構成炭素同志が隣り合って結合している状態をいう。
(1)水素、
(2)フッ素、
(3)水酸基、
(4)C1-3アルキル(該アルキルはフッ素で置換されていてもよい)、
(5)C3-6シクロアルキル(該シクロアルキルはフッ素で置換されていてもよい)であるか、あるいは、
R4及びR5が同一の炭素原子上又は隣接する炭素原子上に存在する場合、
(6)それらが結合する炭素原子と一緒になってC3-6シクロアルキル(該シクロアルキルはフッ素及びC1-3アルキルからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基を形成してもよい場合
が挙げられる。
(1)水素、
(2)フッ素、
(3)塩素、
(4)臭素、
(5)シアノ、
(6)C1-3アルキル(該アルキルはフッ素で置換されていてもよい)、または
(7)C1-3アルコキシ(該アルコキシはフッ素で置換されていてもよい)
が挙げられる。
(1)水素、
(2)フッ素、
(3)塩素、または
(4)シアノ
が挙げられる。
(A)
R1が以下のいずれかであり、
(1)C1-3アルキル(該アルキルはフッ素、水酸基、C3-6シクロアルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)、
(2)C3-6シクロアルキル(該シクロアルキルはフッ素、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)であるか、あるいは、
(3)R2及びR3が結合する炭素原子と一緒になってC3-6シクロアルキル(該シクロアルキルはフッ素、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基、または
(4)R2及びR3が結合する炭素原子と一緒になって窒素原子及び酸素原子からなる群から独立して選択される1または2個のヘテロ原子を含むC4-6飽和複素環(該飽和複素環はハロゲン、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基
であり、
X、Y、Zを含むヘテロアリールが、以下の(5a)~(5c)のいずれかであり、
Q2が、水素、フッ素、塩素、シアノ、C1-3アルキル(該アルキルはフッ素、C3-6シクロアルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)、またはC1-3アルコキシ(該アルコキシはフッ素、C3-6シクロアルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)
である、化合物又はその製薬学的に許容される塩。
(B)
R1が以下の(4)であり、
(1)水素、
(2)ハロゲン、
(3)水酸基、
(4)C1-3アルキル(該アルキルはハロゲン、水酸基、C3-6シクロアルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)、
(5)C3-6シクロアルキル(該シクロアルキルはハロゲン、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)であるか、あるいは、
R4及びR5が結合する炭素原子上または隣接する炭素原子上に存在する場合、
(6)それらが結合する炭素原子と一緒になってC3-6シクロアルキル(該シクロアルキルはハロゲン、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基、または
(7)それらが結合する炭素原子と一緒になって窒素原子及び酸素原子からなる群から独立して選択される1または2個のヘテロ原子を含むC4-6飽和複素環(該シクロアルキルはハロゲン、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基を形成してもよく、
X、Y、Zを含むヘテロアリールが、以下の(5a)~(5c)のいずれかであり、
Q2が、水素、フッ素、塩素、シアノ、C1-3アルキル(該アルキルはフッ素、C3-6シクロアルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)、C1-3アルコキシ(該アルコキシはフッ素、C3-6シクロアルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)であり、
nの好ましい態様としては0、1、2の整数
である、化合物又はその製薬学的に許容される塩。
(C)
R1が以下のいずれかであり、
(1)C1-3アルキル(該アルキルはフッ素で置換されていてもよい)であるか、あるいは、
(2)それらが結合する炭素原子と一緒になってC3-6シクロアルキル(該シクロアルキルはフッ素で置換されていてもよい)を構成した基、または
(3)窒素原子及び酸素原子からなる群から独立して選択される1または2個のヘテロ原子を含むC4-6飽和複素環(該飽和複素環はフッ素で置換されていてもよい)を構成した基
であり、
X、Y、Zを含むヘテロアリールが、以下の(5a)または(5b)であり、
Q2が、水素、フッ素、塩素、シアノである化合物又はその製薬学的に許容される塩。
(D)
R1が以下の(4)であり、
(1)水素、
(2)フッ素、
(3)水酸基、
(4)C1-3アルキル(該アルキルはフッ素で置換されていてもよい)、
(5)C3-6シクロアルキル(該シクロアルキルはフッ素で置換されていてもよい)であるか、あるいは、
R4及びR5が同一の炭素原子上又は隣接する炭素原子上に存在する場合、
(6)それらが結合する炭素原子と一緒になってC3-6シクロアルキル(該シクロアルキルはフッ素及びC1-3アルキルからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基を形成してもよく、
X、Y、Zを含むヘテロアリールが、以下の(5a)または(5b)であり、
Q2が、水素、フッ素、塩素、シアノである化合物又はその製薬学的に許容される塩。
本発明には、式(1)で表される化合物、又はその製薬学的に許容される塩が含まれる。また、本発明の化合物は、水和物及び/又は各種溶媒との溶媒和物(エタノール和物等)の形で存在することもあるので、これらの水和物及び/又は溶媒和物も本発明の化合物に含まれる。さらに、本発明には、本発明の化合物(1)のあらゆる互変異性体、存在するあらゆる立体異性体、及びあらゆる様態の結晶形のもの、さらにこれらの混合物も含まれる。
式(I)の化合物のうち、下記式(1b)の化合物は、下記製造法により製造することができる。
前記製造法1で用いられる化合物(IIa)は、下記反応式で示される方法に従って製造される。
化合物(IIIa)は、化合物(IVa)をアルキル化することにより得られる。工程1のアルキル化反応は、常法に従って行うことができる。例えば、この反応は適当な溶媒中、塩基存在下で化合物(IVa)と、R2XまたはR3Xで表されるアルキルハライドまたはシクロアルキルハライドと反応させる事により行われる。また、R2およびR3が結合する炭素原子と一緒になってC3-6シクロアルキルまたは4-6員の飽和複素環を形成した化合物については、上記反応条件において化合物(IVa)と、対応するジハロゲン化物(例えば、X-(CH2)n-X(nは3~6の整数を表し、Xはハロゲンを表す))を反応させることにより行われる。溶媒の具体例としては、原料化合物の種類等に従って選択されるべきであるが、例えばTHF、ジオキサン、DME、アセトニトリル、DMF、トルエン、酢酸エチル、酢酸イソプロピル等が挙げられ、単独あるいは混合溶媒として使用することができる。使用される塩基の具体例としては、水酸化ナトリウム、水酸化カリウム、水酸化リチウム等の水酸化アルカリ金属、水素化ナトリウム、水素化カリウム等のアルカリ金属ヒドリド、t-ブトキシカリウム、ナトリウムメトキシド等のアルコキシアルカリ金属、炭酸ナトリウム、炭酸水素ナトリウム、炭酸カリウム、炭酸セシウム等の炭酸アルカリ金属が挙げられる。反応温度は、用いられる原料化合物及び試薬の種類等によって異なるが、通常0~200℃、好ましくは20~150℃である。反応時間は、通常30分~24時間である。
化合物(IIa)は、化合物(IIIa)を加水分解することにより得られる。工程2の加水分解反応は、常法に従って行うことができる。例えば、この反応は適当な溶媒中で酸性又は塩基性条件下に化合物(IIIa)と水とを接触させることにより行われる。溶媒の具体例としては、原料化合物の種類等に従って選択されるべきであるが、例えばTHF、ジオキサン、DME、アセトン、アセトニトリル、DMF、DMSO、メタノール、エタノール、イソプロパノール、水等が挙げられ、単独あるいは混合溶媒として使用することができる。使用される酸の具体例としては、塩酸、硫酸等の鉱酸が挙げられる。また、使用される塩基の具体例としては、水酸化ナトリウム、水酸化カリウム、水酸化リチウム等の水酸化アルカリ金属、t-ブトキシカリウム等のアルコキシアルカリ金属、炭酸ナトリウム、炭酸カリウム、炭酸リチウム等の炭酸アルカリ金属が挙げられる。反応温度は、用いられる原料化合物及び試薬の種類等によって異なるが、通常0~150℃、好ましくは20~100℃である。反応時間は、通常30分~24時間である。
前記製造法5で用いられる化合物(IIIa)のうち、(IIIa’)は、化合物(IIIa1)と化合物(IIIa2)との縮合脱水環化反応により製造される。
前記製造法5で用いられる化合物(IVa)のうち、(IVa’)は、化合物(IVa1)と化合物(IVa2)との縮合脱水環化反応により製造される。
前記製造法5で用いられる化合物(IVa)のうち、(IVa’’)は、化合物(IVa3)と化合物(IVa4)との縮合脱水環化反応により製造される。
前記製造法5で用いられる化合物(IVa)のうち、(IVa’’’)は、化合物(IVa5)と化合物(IVa6)との縮合脱水環化反応により製造される。
前記製造法2で用いられる化合物(IIb)は、下記反応式で示される方法に従って製造される。
化合物(IVb)は、化合物(Vb)と亜硫酸ナトリウムとを反応させることにより得られる。工程1の置換反応は、常法に従って行うことができる。例えば、この反応は適当な溶媒中で亜硫酸ナトリウムを接触させることにより行われる。溶媒の具体例としては、原料化合物の種類等に従って選択されるべきであるが、例えばEt2O、THF、ジオキサン、DME等のエーテル類やメタノール、エタノール、イソプロピルアルコール等のアルコール類、トルエン等が挙げられ、単独あるいは混合溶媒として使用することができる。反応温度は、用いられる原料化合物及び試薬の種類等によって異なるが、通常-100℃~200℃、好ましくは0℃~150℃である。反応時間は、通常30分~24時間である。
化合物(IIIb)は、化合物(IVb)をスルホンアミド化することにより得られる。工程2のスルホンアミド化は、常法に従って行うことができる。例えば、この反応は化合物(IVb)をスルホニルクロリドに変換後、アミンと反応させることによって達成される。スルホニルクロリドへの変換は溶媒中又は無溶媒中でオキシ塩化リンを作用させることにより行われる。溶媒の具体例としては、原料化合物の種類等に従って選択されるべきであるが、例えばEt2O、THF、ジオキサン、DME、トルエン等が挙げられ、単独あるいは混合溶媒として使用することができる。反応温度は、用いられる原料化合物及び試薬の種類等によって異なるが、通常-100℃~200℃、好ましくは0℃~150℃である。反応時間は、通常30分~24時間である。
化合物(IIb)は、化合物(IIIb)をアルキル化することにより得られる。化合物(IIb)は、化合物(IIIb)を用いて、製造法5工程1に記載の方法に準じて製造される。
前記製造法10で用いられる化合物(Vb)のうち、(Vb’’’)は、化合物(Vb5)と化合物(Vb6)との縮合脱水環化反応により製造される。
前記製造法3で用いられる化合物(IIc)のうち、(IIc’)は、化合物(IIc1)と化合物(IIc2)との縮合脱水環化反応により製造される。
前記製造法3で用いられる化合物(IIc)のうち、(IIc’’)は、化合物(IIc3)と化合物(IIc4)との縮合脱水環化反応により製造される。
前記製造法3で用いられる化合物(IIc)のうち、(IIc’’’)は、化合物(IIc5)と化合物(IIc6)との縮合脱水環化反応により製造される。
再結晶溶媒としては、例えば、メタノール、エタノール若しくは2-プロパノール等のアルコール系溶媒、ジエチルエーテル等のエーテル系溶媒、酢酸エチル等のエステル系溶媒、ベンゼン若しくはトルエン等の芳香族炭化水素系溶媒、アセトン等のケトン系溶媒、ジクロロメタン若しくはクロロホルム等のハロゲン系溶媒、ヘキサン等の炭化水素系溶媒、ジメチルホルムアミド若しくはアセトニトリル等の非プロトン系溶媒、水、又はこれらの混合溶媒等を用いることができる。その他の精製方法としては、実験化学講座(日本化学会編、丸善)1巻等に記載された方法等を用いることができる。また、本発明の化合物の分子構造の決定は、それぞれの原料化合物に由来する構造を参照して、核磁気共鳴法、赤外吸収法、円二色性スペクトル分析法等の分光学的手法、及び質量分析法により容易に行える。
なお、本発明において、「予防」とは、疾患を発症していない健常人に対して本発明の有効成分を投与する行為であり、例えば、疾患の発症を防止することを目的とするものである。「治療」とは、医師により疾患を発症していると診断をされた人(患者)に対して本発明の有効成分を投与する行為である。かかる疾患に罹患している患者が、かかる疾患に関連する発作を抑えるために服用する行為も、ここでの「予防」または「治療」に該当する。
また、本発明の新規オキサジアゾール誘導体は、E/Iバランスにおける興奮(E)が亢進している及び/又は抑制(I)が低下している疾患の治療剤及び/又は予防剤となり得る。
神経系疾患又は精神疾患としては、てんかん、神経障害性疼痛、神経発達障害群 、双極性障害および関連障害群、統合失調症スペクトラム障害、アルツハイマー病やその他神経認知障害群、筋萎縮性側索硬化症、パーキンソン病、抑うつ症候群、不安症群、強迫性障害、心的外傷およびストレス因関連障害、睡眠-覚醒障害群、及び/又はパーキンソン病・レビー小体型認知症に伴うレム睡眠障害が挙げられる。
GABA神経系機能低下が関与する疾患としては、てんかん、神経障害性疼痛、神経発達障害群、双極性障害および関連障害群、統合失調症スペクトラム障害、アルツハイマー病やその他神経認知障害群、筋萎縮性側索硬化症、パーキンソン病、抑うつ症候群、不安症群、強迫性障害、心的外傷およびストレス因関連障害、睡眠-覚醒障害群、及び/又はパーキンソン病・レビー小体型認知症に伴うレム睡眠障害が挙げられる。
添加剤は、目的に応じて、賦形剤、崩壊剤、結合剤、流動化剤、滑沢剤、コーティング剤、溶解剤、溶解補助剤、増粘剤、分散剤、安定化剤、甘味剤、香料等を用いることができる。具体的には、例えば、乳糖、マンニトール、結晶セルロース、低置換度ヒドロキシプロピルセルロース、トウモロコシデンプン、部分α化デンプン、カルメロースカルシウム、クロスカルメロースナトリウム、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルアルコール、ステアリン酸マグネシウム、フマル酸ステアリルナトリウム、ポリエチレングリコール、プロピレングリコール、酸化チタン、タルク等が挙げられる。
カラム:ACQUITY UPLC BEH C18 1.7μm 2.1 × 30 mm column
溶媒:A液:0.05% HCOOH/H2O、B液:CH3CN
グラジエント条件:
0.0-1.3分;A/B=90/10~5/95(linear gradient)
1.3-1.5分;A/B=90/10
流速:0.80mL/min
UV:220nm、254nm
カラム温度:40℃
1H-NMR (CDCl3)δ: 1.25 (t, 3H), 2.08-2.23 (m, 2H), 2.76-2.84 (m, 2H), 2.86-2.94 (m, 2H), 4.24 (q, 2H), 7.45-7.48 (m, 2H), 8.04-8.07 (m, 2H).
1H-NMR (CDCl3)δ: 1.28 (t, 3H), 3.86 (s, 2H), 4.23 (q, 2H), 7.49 (d, 2H), 8.05 (d, 2H).
1H-NMR (CDCl3)δ: 1.28 (t, 3H), 4.01 (s, 2H), 4.23 (q, 2H), 7.45-7.50 (m, 2H), 7.96-7.99 (m, 2H).
1H-NMR (CDCl3)δ: 1.21 (t, 3H), 1.67 (s, 6H), 4.17 (q, 2H), 7.47-7.50 (m, 2H), 8.04-8.07 (m, 2H).
1H-NMR (CDCl3)δ: 1.78 (s, 6H), 7.42-7.46 (m, 2H), 8.00-8.03 (m, 2H).
MS (m/z) 317 (MNa-), Rt = 0.52 min.
1H-NMR (CDCl3)δ: 3.78 (s, 12H), 4.38 (s, 2H), 4.38 (s, 4H), 6.43-6.46 (m, 4H), 7.20 (d, 2H), 7.58-7.61 (m, 2H),7.89-7.93 (m, 2H).
1H-NMR (CDCl3)δ: 1.93 (s, 6H), 3.57 (s, 6H), 3.71 (s, 6H), 4.27 (br s, 4H), 5.43 (br s, 1H), 6.77 (br s, 1H), 7.14-7.19 (m, 2H), 8.05-8.10 (m, 2H).
1H-NMR (d6-DMSO) δ: 2.21-2.40 (m, 3H), 2.51-2.62 (m, 1H), 5.09-5.12 (m, 1H), 7.38-7.44 (m, 2H), 8.04-8.09 (m, 2H), 8.37 (br s, 1H).
1H-NMR (CDCl3)δ: 1.75 (s, 6H), 5.43 (br s, 1H),6.77 (br s, 1H), 7.14-7.19 (m, 2H), 8.05-8.10 (m, 2H).
MS (m/z) 250 (MH+), Rt = 0.69 min.
1H-NMR (CDCl3)δ: 1.98 (s, 6H), 4.95 (br s, 2H), 7.14-7.19 (m, 2H), 8.03-8.08 (m, 2H).
MS (m/z) 286 (MH+), Rt = 0.71 min.
1H-NMR (CDCl3)δ: 2.27-2.33 (m, 1H), 2.40-2.67 (m, 3H), 2.85 (s,3H), 4.84-4.87 (m, 1H), 7.09-7.15 (m, 2H), 7.99-8.04 (m, 2H).
MS (m/z) 262 (MH+), Rt = 0.71 min.
実施例31(エナンチオマーA):保持時間 4.78分 Chiral HPLC (ChiralpakTM AD-H, 0.46 cm I.D. x 25 cm L, 移動相:100% MeCN、流量:1.0 ml/min、温度:40℃、波長:237 nm)
実施例32(エナンチオマーB):保持時間 5.99分 Chiral HPLC (ChiralpakTM AD-H, 0.46 cm I.D. x 25 cm L, 移動相:100% MeCN、流量:1.0 ml/min、温度:40℃、波長:237 nm)
4-フルオロベンズアミドキシム(840g)、(S)-2-ピロリドン-5-カルボン酸(1.08kg)、N,N-ジイソプロピルエチルアミン(2.56L)と酢酸エチル(7.3L)の混合物に、プロパンホスホン酸無水物の50%酢酸エチル溶液(4.48kg)を加え、室温で1.5時間、続いて75℃加温下で2.5時間撹拌した。放冷後、反応溶液に0.1mol/L塩酸(3.36L)を加えて分液し、水層を酢酸エチル(1.86L)で2回抽出した。有機層を合一し、5%リン酸水素二カリウム水溶液(3.36kg)、水(1.68L)で順次洗浄したのち、有機層を3.36kgまで減圧濃縮し、攪拌しつつ0℃まで冷却した。生じたスラリーにn-ヘプタン(3.02kg)を滴下し、結晶を濾過で集め、40%酢酸エチル/ヘプタン混合溶媒(1.68kg)で洗浄、40℃で真空乾燥することにより、粗結晶(1.14g)を淡褐色固体として得た。この粗結晶(1.00kg)を2-プロパノール/水(50%、1.6kg)に溶解後、活性炭60gを加えて25℃で攪拌し、活性炭を濾過で除いた。濾液を2-プロパノール/水(50%)で3.0kgになるよう希釈し、0℃の水(6.0L)に攪拌しながら滴下した。結晶を濾過で集め、2-プロパノール/水混合溶媒(12.5%、2.0kg)で洗浄後、40℃で真空乾燥することにより、実施例33の化合物(944g)を白色固体として得た。NMRとHPLCの確認により、この化合物が実施例31の化合物と同一であることを確認した。
抗てんかん薬の評価には、臨床予測性の高い皮下注射ペンテトラゾールモデル(最小痙攣モデル、scPTZ)評価が用いられる。このモデルにおいて抗痙攣作用を示す化合物は、臨床において抗てんかん薬として期待される。この試験では、全般性の欠神発作やミオクロニー発作の表現系である動物モデルを用いた。Slc:ddY系雄性マウス(日本エス エル シー株式会社より入手、一群5匹、体重20~30g)に被験化合物を経口投与し、1時間後にペンテトラゾール85mg/kgを皮下投与した。その後、30分間における間代性痙攣の発現の有無を観察した。なお、コントロールは被験化合物として0.5%メチルセルロース液を投与して、同様の試験を行った。結果を以下の表12に示した。5匹中、痙攣の発現抑制を示した匹数で表した。コントロールは、5匹中4匹痙攣を発現した場合に試験成立とした。
本試験は、薬物の協調運動能抑制作用を評価する試験である。ローターロッドとは、直径4cmの円柱棒を回転させる装置で、回転した棒の上でマウスを歩行させ、その歩行の可否を指標に協調運動能を評価する。Slc:ddy系雄性マウス(日本エス エル シー株式会社より入手、体重20~30g)を、試験3時間前に12回転/分で回転したローターロッド装置上を5分間落下しないで歩行できるように訓練し、歩行可能なマウスのみを試験に使用する。一群5匹に被験化合物を経口投与し、1時間後に15回/分で回転したローターロッド装置に乗せ、180秒間歩行状態を観察し歩行時間を計測した。なお、コントロールは被験化合物として0.5%メチルセルロース液を投与して、同様の試験を行った。協調運動能は、5匹の歩行時間(秒)の平均値で表した。結果を表13に示した。コントロールは180秒間歩行可能であった。
本試験は、薬物のドラベモデルマウス熱性痙攣に対する抗痙攣作用を評価する試験である。この試験では、BALB/c-Scn1a<+/->マウス(カタログ番号:RBRC06422;文部科学省ナショナルバイオリソースプロジェクトを介して、国立研究開発法人理化学研究所バイオリソースセンターから提供を受けることができる。)を用いた。本モデルマウスは、ドラベ症候群患者の原因遺伝子であるScn1Aに変異を持ち、ドラベ症候群患者の症状である体温上昇による熱性痙攣と類似した病態を呈する表現型であり、自然発症ドラベ症候群のモデル動物として使用することができる(参考:てんかん治療研究振興財団 研究年報 2015:26:69-76)。ドラベモデル雄性マウス(一群5~8匹、体重20~30g)に被験化合物を経口投与し、50分後に湯浴につけたチャンバー内に入れ体温上昇を惹起し、熱性痙攣の発現を観察した。熱性痙攣の発現後素早く直腸内体温を測定し、痙攣閾値体温とした。なお、コントロールは被験化合物として0.5%メチルセルロース液を投与して、同様の試験を行った。抗痙攣活性は、コントロール群に比して痙攣閾値体温を有意に上昇させる薬物用量と、コントロール群との痙攣閾値体温の差として表した。結果を表14に示した。
本試験は、安定型細胞株作成のガイドライン(ロンザジャパンのウェブサイト;非特許文献4)に記載の方法で取得できるGABA-A受容体発現細胞を用い、GABAにより惹起される電流を指標に薬物のGABA-A受容体賦活化作用を評価する試験である。GABA-A受容体発現細胞を電気生理学実験に供し、2 μMのGABA溶液、引き続き2 μMのGABAと被験化合物の混合液を添加した時に見られる電流を測定した。GABA賦活化活性は、2 μMのGABAと被験化合物の混合液を添加したときに見られる電流の、GABAのみで見られる電流に対する増加率で示し、電流を20%増加させる被験化合物の濃度をEC20で表した。また同様に、2 μMのGABAと被験化合物に10 μMのフルマゼニル混合液を添加した時に見られる電流を測定し、フルマゼニル非存在下での電流増加に対するフルマゼニルによる阻害率を算出した。結果を表15に示した。
本試験は、薬物の抗うつ効果を評価する試験である。ラットを逃避不可能な水槽に投入して水泳させると、逃避行動の後に無動が認められる。翌日に再度水槽内にラットを入れると、初回より早期に無動が出現する。この無動時間の持続時間をうつ様行動として、被験化合物の抗うつ効果を評価する方法である。Wister系雄性ラット(日本チャールス・リバー株式会社より入手、体重260~300g)を、試験前日に15分間水槽内で水泳させた。試験当日、被験化合物を経口投与し(一群10~12匹)、1時間後に再度水槽内で5分水泳させ無動時間を計測した。なお、コントロール群は被験化合物として0.5%メチルセルロース液を投与して、同様の試験を行った。抗うつ活性は、コントロール群に対する無動時間の減少率の平均値で表した。結果を表16に示した。
Claims (20)
- 式(1)で表される化合物、又はその製薬学的に許容される塩。
Q1はハロゲンを表し、
Q2は水素、ハロゲン、シアノ、C1-3アルキル(該アルキルはハロゲン、水酸基、C3-6シクロアルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)又はC1-3アルコキシ(該アルコキシはハロゲン、水酸基、C3-6シクロアルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を表し、
X、Y及びZは、同一又は異なって、窒素原子又は酸素原子を表し、ただし、X、Y及びZを含む環は、X、Y及びZのうちの2つが窒素原子であり、残りの1つが酸素原子であるヘテロアリールであり、
R1は以下の(2)~(4)のいずれかを表し、
R4及びR5は、同一又は異なって、水素、ハロゲン、水酸基、C1-6アルキル(該アルキルはハロゲン、水酸基、C3-6シクロアルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)、又はC3-6シクロアルキル(該シクロアルキルはハロゲン、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を表すか、あるいは、R4及びR5が同一の炭素原子上又は隣接する炭素原子上に存在する場合、それらが結合する炭素原子と一緒になってC3-6シクロアルキル(該シクロアルキルはハロゲン、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)又は窒素原子及び酸素原子からなる群から独立して選択される1または2個のヘテロ原子を含むC4-6飽和複素環(該飽和複素環はハロゲン、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基を形成してもよく、
nは、0~2の整数を表す。] - R2及びR3が、同一又は異なって、C1-3アルキル(該アルキルはフッ素、水酸基及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を表すか、あるいは、それらが結合する炭素原子と一緒になってC3-6シクロアルキル(該シクロアルキルはフッ素、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基、又は窒素原子及び酸素原子からなる群から独立して選択される1または2個のヘテロ原子を含むC4-6飽和複素環(該飽和複素環はフッ素、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基である、
請求項1に記載の化合物又はその製薬学的に許容される塩。 - R2及びR3が、同一又は異なって、C1-3アルキル(該アルキルはフッ素で置換されていてもよい)を表すか、あるいは、それらが結合する炭素原子と一緒になってC3-6シクロアルキル(該シクロアルキルはフッ素で置換されていてもよい)を構成した基、又は窒素原子及び酸素原子からなる群から独立して選択される1または2個のヘテロ原子を含むC4-6飽和複素環(該飽和複素環はフッ素で置換されていてもよい)を構成した基である、
請求項2に記載の化合物又はその製薬学的に許容される塩。 - R4及びR5が、同一又は異なって、水素、フッ素、水酸基、C1-3アルキル(該アルキルはフッ素、水酸基、及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)、又はC3-6シクロアルキル(該シクロアルキルはフッ素、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を表すか、あるいは、R4及びR5が同一の炭素原子上又は隣接する炭素原子上に存在する場合、それらが結合する炭素原子と一緒になってC3-6シクロアルキル(該シクロアルキルはフッ素、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基、又は窒素原子及び酸素原子からなる群から独立して選択される1または2個のヘテロ原子を含むC4-6飽和複素環(該飽和複素環はフッ素、水酸基、C1-3アルキル及びC1-3アルコキシからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基を形成してもよい、
請求項1~3のいずれか一項に記載の化合物又はその製薬学的に許容される塩。 - R4及びR5が、同一又は異なって、水素、フッ素、水酸基、C1-3アルキル(該アルキルはフッ素で置換されていてもよい)、又はC3-6シクロアルキル(該シクロアルキルはフッ素で置換されていてもよい)を表すか、あるいは、R4及びR5が同一の炭素原子上又は隣接する炭素原子上に存在する場合、それらが結合する炭素原子と一緒になってC3-6シクロアルキル(該シクロアルキルはフッ素及びC1-3アルキルからなる群から独立して選択される1~3個の置換基で置換されていてもよい)を構成した基を形成してもよい、
請求項4に記載の化合物又はその製薬学的に許容される塩。 - Q1がフッ素、塩素又は臭素であり、
Q2が水素、フッ素、塩素、臭素、シアノ、C1-3アルキル(該アルキルはフッ素で置換されていてもよい)又はC1-3アルコキシ(該アルコキシはフッ素で置換されていてもよい)である、
請求項1~5のいずれか一項に記載の化合物又はその製薬学的に許容される塩。 - 以下の化合物から選択される、請求項1に記載の化合物又はその製薬学的に許容される塩:
2-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-2-メチルプロパンアミド、
2-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]-2-メチルプロパンアミド、
2-[3-(4-ブロモフェニル)-1,2,4-オキサジアゾール-5-イル]-2-メチルプロパンアミド、
1-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]シクロプロパン-1-カルボキサミド、
1-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]シクロプロパン-1-カルボキサミド、
1-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]-3-フルオロシクロブタン-1-カルボキサミド、
1-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]-3,3-ジフルオロシクロブタン-1-カルボキサミド、
1-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]シクロブタン-1-カルボキサミド、
1-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]シクロペンタン-1-カルボキサミド、
4-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]テトラヒドロ-2H-ピラン-4-カルボキサミド、
2-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]-2-エチルブタンアミド、
2-[5-(4-フルオロフェニル)-1,2,4-オキサジアゾール-3-イル]-2-メチルプロパンアミド、
2-[5-(4-クロロフェニル)-1,2,4-オキサジアゾール-3-イル]-2-メチルプロパンアミド、
2-[5-(4-ブロモフェニル)-1,2,4-オキサジアゾール-3-イル]-2-メチルプロパンアミド、
2-[5-(4-クロロフェニル)-1,3,4-オキサジアゾール-2-イル]-2-メチルプロパンアミド、
2-[5-(4-ブロモフェニル)-1,3,4-オキサジアゾール-2-イル]-2-メチルプロパンアミド、
2-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]プロパン-2-スルホンアミド、
2-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]プロパン-2-スルホンアミド、
2-[3-(4-ブロモフェニル)-1,2,4-オキサジアゾール-5-イル]プロパン-2-スルホンアミド、
2-[5-(4-クロロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-スルホンアミド、
2-[5-(4-ブロモフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-スルホンアミド、
2-[5-(4-フルオロフェニル)-1,3,4-オキサジアゾール-2-イル]プロパン-2-スルホンアミド、
2-[5-(4-クロロフェニル)-1,3,4-オキサジアゾール-2-イル]プロパン-2-スルホンアミド、
2-[5-(4-ブロモフェニル)-1,3,4-オキサジアゾール-2-イル]プロパン-2-スルホンアミド、
5-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン、
5-[3-(2,4-ジフルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン、
5-[3-(3,4-ジフルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン、
5-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1,5-ジメチルピロリジン-2-オン、
5-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン、
5-[3-(4-ブロモフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン、
(S)-5-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン、及び
(R)-5-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン。 - 以下の化合物から選択される、請求項1に記載の化合物又はその製薬学的に許容される塩:
2-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]-2-メチルプロパンアミド、
2-[3-(4-ブロモフェニル)-1,2,4-オキサジアゾール-5-イル]-2-メチルプロパンアミド、
2-[5-(4-クロロフェニル)-1,2,4-オキサジアゾール-3-イル]-2-メチルプロパンアミド、
2-[5-(4-クロロフェニル)-1,2,4-オキサジアゾール-3-イル]プロパン-2-スルホンアミド、
5-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン、
5-[3-(4-クロロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン、
(S)-5-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン、及び
(R)-5-[3-(4-フルオロフェニル)-1,2,4-オキサジアゾール-5-イル]-1-メチルピロリジン-2-オン。 - 請求項1~11のいずれか一項に記載の化合物、又はその製薬学的に許容される塩を含有する医薬組成物。
- 請求項1~11のいずれか一項に記載の化合物、又はその製薬学的に許容される塩を有効成分として含有するGABA神経系機能低下が関与する疾患の治療剤及び/又は予防剤。
- GABA神経系機能低下が関与する疾患が、神経系疾患又は精神疾患である、請求項13に記載の治療剤及び/又は予防剤。
- 神経系疾患または精神疾患が、てんかん、神経障害性疼痛、神経発達障害群、双極性障害および関連障害群、統合失調症スペクトラム障害、アルツハイマー病やその他神経認知障害群、筋萎縮性側索硬化症、パーキンソン病、抑うつ症候群、不安症群、強迫性障害、心的外傷およびストレス因関連障害、睡眠-覚醒障害群、及び/又はパーキンソン病・レビー小体型認知症に伴うレム睡眠障害である、請求項14に記載の治療剤及び/又は予防剤。
- 治療が必要な患者に、治療上の有効量の請求項1~11のいずれか一項に記載の化合物、又はその製薬学的に許容される塩を投与することを含む、GABA神経系機能低下が関与する疾患の治療及び/又は予防するための方法。
- GABA神経系機能低下が関与する疾患の治療剤及び/又は予防剤を製造するための、請求項1~11のいずれか一項に記載の化合物、又はその製薬学的に許容される塩の使用。
- GABA神経系機能低下が関与する疾患の治療及び/又は予防に使用するための、請求項1~11のいずれか一項に記載の化合物、又はその製薬学的に許容される塩。
- 請求項1~11のいずれか一項に記載の化合物又はその製薬学的に許容される塩を含有する医薬と、抗てんかん薬、抗うつ薬、又は抗精神病薬に分類される薬剤から選択される少なくとも1種以上の薬剤とを組み合わせてなる医薬。
- 抗てんかん薬、抗うつ薬、又は抗精神病薬に分類される薬剤から選択される少なくとも1種以上の薬剤と併用することを特徴とする、GABA神経系機能低下が関与する疾患を治療するための、請求項1~11のいずれか一項に記載の化合物又はその製薬学的に許容される塩を含有する医薬。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022508381A JPWO2021187486A1 (ja) | 2020-03-17 | 2021-03-16 | |
MX2022011483A MX2022011483A (es) | 2020-03-17 | 2021-03-16 | Derivado de oxadiazol. |
EP21770862.7A EP4122923A4 (en) | 2020-03-17 | 2021-03-16 | OXADIAZOLE DERIVATIVE |
BR112022017530A BR112022017530A2 (pt) | 2020-03-17 | 2021-03-16 | Derivado de oxadiazol |
KR1020227035750A KR20220154208A (ko) | 2020-03-17 | 2021-03-16 | 옥사디아졸 유도체 |
CN202180036916.0A CN115515943A (zh) | 2020-03-17 | 2021-03-16 | 噁二唑衍生物 |
US17/905,847 US20230265061A1 (en) | 2020-03-17 | 2021-03-16 | Oxadiazole derivative |
CA3170273A CA3170273A1 (en) | 2020-03-17 | 2021-03-16 | Oxadiazole derivative |
AU2021239631A AU2021239631A1 (en) | 2020-03-17 | 2021-03-16 | Oxadiazole derivative |
US17/932,871 US11718592B2 (en) | 2020-03-17 | 2022-09-16 | Oxadiazole derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020046138 | 2020-03-17 | ||
JP2020-046138 | 2020-03-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/905,847 A-371-Of-International US20230265061A1 (en) | 2020-03-17 | 2021-03-16 | Oxadiazole derivative |
US17/932,871 Continuation US11718592B2 (en) | 2020-03-17 | 2022-09-16 | Oxadiazole derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021187486A1 true WO2021187486A1 (ja) | 2021-09-23 |
Family
ID=77768228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/010628 WO2021187486A1 (ja) | 2020-03-17 | 2021-03-16 | オキサジアゾール誘導体 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20230265061A1 (ja) |
EP (1) | EP4122923A4 (ja) |
JP (1) | JPWO2021187486A1 (ja) |
KR (1) | KR20220154208A (ja) |
CN (1) | CN115515943A (ja) |
AU (1) | AU2021239631A1 (ja) |
BR (1) | BR112022017530A2 (ja) |
CA (1) | CA3170273A1 (ja) |
MX (1) | MX2022011483A (ja) |
TW (1) | TW202146392A (ja) |
WO (1) | WO2021187486A1 (ja) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006138512A2 (en) | 2005-06-15 | 2006-12-28 | Senomyx, Inc. | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants and taste enhancers |
WO2010017132A1 (en) * | 2008-08-04 | 2010-02-11 | Chdi, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
WO2013062027A1 (ja) * | 2011-10-27 | 2013-05-02 | 大正製薬株式会社 | アゾール誘導体 |
WO2014072957A1 (en) * | 2012-11-12 | 2014-05-15 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
JP2014525444A (ja) * | 2011-09-01 | 2014-09-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | c−kitキナーゼインヒビターとしての化合物及び組成物 |
JP2014224108A (ja) * | 2013-04-26 | 2014-12-04 | 大正製薬株式会社 | アゾール誘導体を含有する医薬 |
WO2015161014A1 (en) * | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
JP2018507886A (ja) * | 2015-03-10 | 2018-03-22 | ジェンザイム・コーポレーション | タンパク質症を処置するための方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ577111A (en) * | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
GB0723814D0 (en) * | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
MX2018005361A (es) * | 2015-10-30 | 2018-06-07 | Ptc Therapeutics Inc | Metodos para tratar epilepsia. |
-
2021
- 2021-03-16 MX MX2022011483A patent/MX2022011483A/es unknown
- 2021-03-16 JP JP2022508381A patent/JPWO2021187486A1/ja active Pending
- 2021-03-16 CA CA3170273A patent/CA3170273A1/en active Pending
- 2021-03-16 KR KR1020227035750A patent/KR20220154208A/ko unknown
- 2021-03-16 US US17/905,847 patent/US20230265061A1/en active Pending
- 2021-03-16 TW TW110109295A patent/TW202146392A/zh unknown
- 2021-03-16 AU AU2021239631A patent/AU2021239631A1/en active Pending
- 2021-03-16 EP EP21770862.7A patent/EP4122923A4/en active Pending
- 2021-03-16 WO PCT/JP2021/010628 patent/WO2021187486A1/ja unknown
- 2021-03-16 CN CN202180036916.0A patent/CN115515943A/zh active Pending
- 2021-03-16 BR BR112022017530A patent/BR112022017530A2/pt unknown
-
2022
- 2022-09-16 US US17/932,871 patent/US11718592B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006138512A2 (en) | 2005-06-15 | 2006-12-28 | Senomyx, Inc. | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants and taste enhancers |
WO2010017132A1 (en) * | 2008-08-04 | 2010-02-11 | Chdi, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
JP2014525444A (ja) * | 2011-09-01 | 2014-09-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | c−kitキナーゼインヒビターとしての化合物及び組成物 |
WO2013062027A1 (ja) * | 2011-10-27 | 2013-05-02 | 大正製薬株式会社 | アゾール誘導体 |
WO2014072957A1 (en) * | 2012-11-12 | 2014-05-15 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
JP2014224108A (ja) * | 2013-04-26 | 2014-12-04 | 大正製薬株式会社 | アゾール誘導体を含有する医薬 |
WO2015161014A1 (en) * | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
JP2018507886A (ja) * | 2015-03-10 | 2018-03-22 | ジェンザイム・コーポレーション | タンパク質症を処置するための方法 |
Non-Patent Citations (43)
Title |
---|
ANNE T. BERG ET AL., EPILEPSIA, vol. 51, no. 4, 2010, pages 676 - 85 |
DATABASE CAS [online] 1 January 2020 (2020-01-01), retrieved from STN Database accession no. 2398023-07-7 * |
DATABASE CAS [online] 12 August 2020 (2020-08-12), retrieved from STN Database accession no. 2456305-65-8 * |
DATABASE CAS [online] 15 December 2019 (2019-12-15), retrieved from STN Database accession no. 2391021-52-4 * |
DATABASE CAS [online] 18 December 2019 (2019-12-18), "Cyclobutanecarboxamide", retrieved from STN Database accession no. 2393258-12-1 * |
DATABASE CAS [online] 19 August 2020 (2020-08-19), retrieved from STN Database accession no. 2459729-04-3 * |
DATABASE CAS [online] 19 June 2020 (2020-06-19), retrieved from STN Database accession no. 2429734-82-5 * |
DATABASE CAS [online] 19 June 2020 (2020-06-19), retrieved from STN Database accession no. 2429736-73-0 * |
DATABASE CAS [online] 2 September 2020 (2020-09-02), retrieved from STN Database accession no. 2470141-73-0 * |
DATABASE CAS [online] 20 August 2020 (2020-08-20), retrieved from STN Database accession no. 2459865-29-1 * |
DATABASE CAS [online] 20 December 2019 (2019-12-20), retrieved from STN Database accession no. 2395139-54-3 * |
DATABASE CAS [online] 20 December 2019 (2019-12-20), retrieved from STN Database accession no. 2395140-09-5 * |
DATABASE CAS [online] 24 June 2020 (2020-06-24), retrieved from STN Database accession no. 2433152-21-5 * |
DATABASE CAS [online] 24 June 2020 (2020-06-24), retrieved from STN Database accession no. 2433544-91-1 * |
DATABASE CAS [online] 26 August 2020 (2020-08-26), retrieved from STN Database accession no. 2461806-70-0 * |
DATABASE CAS [online] 26 June 2020 (2020-06-26), retrieved from STN Database accession no. 2434477-84-4 * |
DATABASE CAS [online] 27 August 2020 (2020-08-27), retrieved from STN Database accession no. 2461981-80-4 * |
DATABASE CAS [online] 27 August 2020 (2020-08-27), retrieved from STN Database accession no. 2462268-37-5 * |
DATABASE CAS [online] 27 August 2020 (2020-08-27), retrieved from STN Database accession no. 2463630-55-7 * |
DATABASE CAS [online] 27 August 2020 (2020-08-27), retrieved from STN Database accession no. 2463706-64-9 * |
DATABASE CAS [online] 27 August 2020 (2020-08-27), retrieved from STN Database accession no. 2463745-70-0 * |
DATABASE CAS [online] 27 August 2020 (2020-08-27), retrieved from STN Database accession no. 2463903-64-0 * |
DATABASE CAS [online] 27 August 2020 (2020-08-27), retrieved from STN Database accession no. 2464072-27-1 * |
DATABASE CAS [online] 27 August 2020 (2020-08-27), retrieved from STN Database accession no. 2464868-57-1 * |
DATABASE CAS [online] 27 August 2020 (2020-08-27), retrieved from STN Database accession no. 2465199-54-4 * |
DATABASE CAS [online] 27 August 2020 (2020-08-27), retrieved from STN Database accession no. 2465276-05-3 * |
DATABASE CAS [online] 28 August 2020 (2020-08-28), retrieved from STN Database accession no. 2464618-52-6 * |
DATABASE CAS [online] 28 August 2020 (2020-08-28), retrieved from STN Database accession no. 2465699-93-6 * |
DATABASE CAS [online] 28 August 2020 (2020-08-28), retrieved from STN Database accession no. 2465711-86-6 * |
DATABASE CAS [online] 28 August 2020 (2020-08-28), retrieved from STN Database accession no. 2465992-77-0 * |
DATABASE CAS [online] 28 August 2020 (2020-08-28), retrieved from STN Database accession no. 2466368-39-6 * |
DATABASE CAS [online] 28 August 2020 (2020-08-28), retrieved from STN Database accession no. 2466822-24-0 * |
DATABASE CAS [online] 28 August 2020 (2020-08-28), retrieved from STN Database accession no. 2467263-41-6 * |
DATABASE CAS [online] 28 August 2020 (2020-08-28), retrieved from STN Database accession no. 2467934-22-9 * |
DATABASE CAS [online] 3 September 2019 (2019-09-03), retrieved from STN Database accession no. 2372839-85-3 * |
DATABASE CAS [online] 3 September 2019 (2019-09-03), retrieved from STN Database accession no. 2372841-01-3 * |
DATABASE CAS [online] 5 January 2020 (2020-01-05), retrieved from STN Database accession no. 2399808-57-0 * |
DATABASE CAS [online] 6 August 2020 (2020-08-06), retrieved from STN Database accession no. 2454150-20-8 * |
JAPAN EPILEPSY RESEARCH FOUNDATION, vol. 26, 2015, pages 69 - 76 |
R. C. LAROCK: "Comprehensive Organic Transformations", 1999, JOHN WILEY SONS INC. |
ROBERT S. FISHER ET AL., EPILEPSIA, vol. 58, no. 4, 2017, pages 522 - 530 |
SCHMITZ B., EPILEPSIA, 2005, pages 45 - 49 |
See also references of EP4122923A4 |
Also Published As
Publication number | Publication date |
---|---|
BR112022017530A2 (pt) | 2022-10-18 |
AU2021239631A8 (en) | 2022-12-01 |
US11718592B2 (en) | 2023-08-08 |
MX2022011483A (es) | 2022-10-07 |
US20230265061A1 (en) | 2023-08-24 |
AU2021239631A1 (en) | 2022-11-10 |
CN115515943A (zh) | 2022-12-23 |
US20230092498A1 (en) | 2023-03-23 |
KR20220154208A (ko) | 2022-11-21 |
CA3170273A1 (en) | 2021-09-23 |
EP4122923A4 (en) | 2024-04-24 |
EP4122923A1 (en) | 2023-01-25 |
TW202146392A (zh) | 2021-12-16 |
JPWO2021187486A1 (ja) | 2021-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5408434B2 (ja) | アミド化合物 | |
JP6387023B2 (ja) | 三環式化合物およびその使用 | |
JP5617919B2 (ja) | テトラヒドロベンゾチオフェン化合物 | |
JP6211509B2 (ja) | 複素環化合物およびその用途 | |
TW201738226A (zh) | 雜環化合物 | |
JP5640983B2 (ja) | グリシン化合物 | |
JPWO2017170830A1 (ja) | 複素環化合物 | |
TW200838526A (en) | Carboxylic acid derivatives | |
DK2767531T3 (en) | Cyclic n, n'-diarylthioureas and n, n'-diarylurines as androgen receptor antagonists, anti-cancer agent, method of preparation and use thereof | |
JPWO2004110986A1 (ja) | ベンズアミド誘導体又はその塩 | |
WO2012117421A1 (en) | Histone deacetylase inhibitors | |
MX2007015678A (es) | Antagonistas y agonistas de piperazina-piperidina del receptor 5-ht-1a. | |
KR20090114439A (ko) | 아실구아니딘 유도체 | |
TW202003472A (zh) | 鈣蛋白酶(calpain)調節劑及其醫療用途 | |
MX2013001202A (es) | Compuestos de piridina de anillo fusionado. | |
EA029313B1 (ru) | Производные пиперазина и их применение в качестве лекарственного средства | |
EP2280940A1 (en) | Novel n-(2-amino-phenyl)-acrylamides | |
WO2015092118A1 (en) | Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors | |
WO2021187486A1 (ja) | オキサジアゾール誘導体 | |
WO2018235838A1 (ja) | 複素環化合物 | |
JP2023046323A (ja) | オキサジアゾール誘導体を含有する医薬組成物 | |
EA014694B1 (ru) | Производные карбазола в качестве функциональных 5-htлигандов | |
KR102253721B1 (ko) | 벤조티오펜 화합물 | |
CN110709401A (zh) | 杂环化合物 | |
AU2017376599A1 (en) | Azepane inhibitors of menin-MLL interaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21770862 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3170273 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022508381 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022017530 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20227035750 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112022017530 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220831 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021770862 Country of ref document: EP Effective date: 20221017 |
|
ENP | Entry into the national phase |
Ref document number: 2021239631 Country of ref document: AU Date of ref document: 20210316 Kind code of ref document: A |